Aridis Pharmaceuticals (ARDS) 10-Q 21 Nov 22 2022 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Sep. 30, 2022	Oct. 31, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Sep. 30, 2022
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2022
Current Fiscal Year End Date	--12-31
Entity File Number	001-38630
Entity Registrant Name	Aridis Pharmaceuticals, Inc.
Entity Central Index Key	0001614067
Entity Tax Identification Number	47-2641188
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	983 University Avenue
Entity Address, Address Line Two	Bldg. B
Entity Address, City or Town	Los Gatos
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	95032
City Area Code	(408)
Local Phone Number	385-1742
Title of 12(b) Security	Common Stock
Trading Symbol	ARDS
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		20,804,800

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 1,886	$ 18,098
Restricted cash	747	1,388
Other receivables	248	237
Contract costs	1,986	1,967
Prepaid asset	3,768	2,700
Total current assets	8,635	24,390
Property and equipment, net	974	1,357
Right-of-use assets, net	1,532
Intangible assets, net	18	22
Restricted cash, non-current	500	500
Contract costs, non-current	78	96
Other assets	383	431
Total assets	12,120	26,796
Current liabilities:
Accounts payable	4,230	5,240
Accrued liabilities	8,494	6,464
Lease liabilities	526
Deferred revenue	20,386	20,838
Note payable	831	696
Notes payable (at fair value)	7,795
Other liabilities	15	110
Total current liabilities	42,277	33,348
Deferred revenue, non-current	737	913
Lease liabilities, non-current	1,430
Notes payable, non-current (at fair value)	3,499	5,282
Other liabilities		363
Total liabilities	47,943	39,906
Stockholders’ deficit:
Preferred stock (par value $0.0001; 60,000,000 shares authorized; zero shares issued and outstanding as of September 30, 2022 and December 31, 2021)
Common stock (par value $0.0001; 100,000,000 shares authorized; 17,701,592 shares issued and outstanding as of September 30, 2022 and December 31, 2021, respectively)	2	2
Additional paid-in capital	153,454	152,183
Accumulated deficit	(189,279)	(165,295)
Total stockholders’ deficit	(35,823)	(13,110)
Total liabilities and stockholders’ deficit	$ 12,120	$ 26,796

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	60,000,000	60,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	17,701,592	17,701,592
Common stock, shares outstanding	17,701,592	17,701,592

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Revenue:
Grant revenue	$ 399	$ 515	$ 1,878	$ 548
Operating expenses:
Research and development	6,118	19,842	18,916	29,370
General and administrative	1,693	1,699	5,535	5,337
Total operating expenses	7,811	21,541	24,451	34,707
Loss from operations	(7,412)	(21,026)	(22,573)	(34,159)
Other income (expense):
Interest income (expense), net	(27)	1	(267)	2
Other income, net	23	23	68	52
Gain on extinguishment of Paycheck Protection Program loan				722
Change in fair value of note payable	(823)		(1,212)
Net loss	(8,239)	(21,002)	(23,984)	(33,383)
Deemed dividends		(3,141)		(4,127)
Net loss available to common stockholders	$ (8,239)	$ (24,143)	$ (23,984)	$ (37,510)
Weighted-average common shares outstanding used in computing net loss per share available to common stockholders, basic and diluted	17,701,592	12,454,119	17,701,592	11,314,058
Net loss per share to common stockholders, basic and diluted	$ (0.47)	$ (1.94)	$ (1.35)	$ (3.32)

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes in Stockholders' Deficit (Unaudited) - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Dec. 31, 2020	$ 1	$ 114,420	$ (123,102)	$ (8,681)
Beginning balance, shares at Dec. 31, 2020	10,065,727
Stock-based compensation		1,700		1,700
Net loss			(33,383)	(33,383)
Issuance of common stock, pre-funded warrants and warrants in registered direct offerings, net of issuance costs		29,711		29,711
Issuance of common stock pre-funded warrants and warrants in registered direct offering, net of issuance costs (in shares)	2,337,405
Issuance of common stock in connection with license agreement		6,460		6,460
Issuance of common stock in connection with license agreement (in shares)	884,956
Deemed dividends
Deemed dividends, shares	759,389
Issuance of common stock for consulting services		33		33
Issuance of common stock for consulting services, shares	5,000
Exercise of stock options		5		$ 5
Exercise of stock options, shares	1,559			0
Ending balance, value at Sep. 30, 2021	$ 1	152,329	(156,485)	$ (4,155)
Ending balance, shares at Sep. 30, 2021	14,054,036
Beginning balance, value at Dec. 31, 2020	$ 1	114,420	(123,102)	(8,681)
Beginning balance, shares at Dec. 31, 2020	10,065,727
Ending balance, value at Dec. 31, 2021	$ 2	152,183	(165,295)	(13,110)
Ending balance, shares at Dec. 31, 2021	17,701,592
Beginning balance, value at Jun. 30, 2021	$ 1	121,995	(135,483)	(13,487)
Beginning balance, shares at Jun. 30, 2021	11,234,480
Stock-based compensation		580		580
Net loss			(21,002)	(21,002)
Issuance of common stock, pre-funded warrants and warrants in registered direct offerings, net of issuance costs		23,294		23,294
Issuance of common stock pre-funded warrants and warrants in registered direct offering, net of issuance costs (in shares)	1,300,000
Issuance of common stock in connection with license agreement		6,460		6,460
Issuance of common stock in connection with license agreement (in shares)	884,956
Deemed dividends
Deemed dividends, shares	634,600
Exercise of stock options, shares				0
Ending balance, value at Sep. 30, 2021	$ 1	152,329	(156,485)	$ (4,155)
Ending balance, shares at Sep. 30, 2021	14,054,036
Beginning balance, value at Dec. 31, 2021	$ 2	152,183	(165,295)	(13,110)
Beginning balance, shares at Dec. 31, 2021	17,701,592
Stock-based compensation		1,161		1,161
Net loss			(23,984)	$ (23,984)
Deemed dividends, shares				0
Issuance of common stock for consulting services		3		$ 3
Stock options issued in exchange for accrued liability		107		$ 107
Exercise of stock options, shares				0
Ending balance, value at Sep. 30, 2022	$ 2	153,454	(189,279)	$ (35,823)
Ending balance, shares at Sep. 30, 2022	17,701,592
Beginning balance, value at Jun. 30, 2022	$ 2	153,105	(181,040)	(27,933)
Beginning balance, shares at Jun. 30, 2022	17,701,592
Stock-based compensation		349		349
Net loss			(8,239)	$ (8,239)
Exercise of stock options, shares				0
Ending balance, value at Sep. 30, 2022	$ 2	$ 153,454	$ (189,279)	$ (35,823)
Ending balance, shares at Sep. 30, 2022	17,701,592

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Cash flows from operating activities:
Net loss	$ (23,984,000)	$ (33,383,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	387,000	278,000
Asset impairment	33,000
Stock-based compensation	1,161,000	1,700,000
Issuance of common stock in connection with license agreement		6,460,000
Issuance of common stock in exchange for consulting services	3,000	33,000
Gain on extinguishment of Paycheck Protection Program loan		(722,000)
Change in fair value of note payable	1,212,000
Non-cash debt issuance expense	250,000
Changes in operating assets and liabilities:
Accounts receivable		(1,000,000)
Other receivables	(11,000)	335,000
Prepaid asset	(132,000)	5,000
Other assets	47,000
Lease liabilities	(19,000)
Accounts payable	(1,010,000)	824,000
Accrued liabilities and other liabilities	2,121,000	5,311,000
Deferred revenue	(628,000)	952,000
Net cash used in operating activities	(20,570,000)	(19,207,000)
Cash flows from investing activities:
Purchase of property and equipment	(33,000)	(573,000)
Net cash used in investing activities	(33,000)	(573,000)
Cash flows from financing activities:
Proceeds from issuance of common stock, net		29,764,000
Proceeds from note payable	5,000,000
Payments on note payable	(450,000)
Net proceeds from financing of insurance premium	(800,000)
Proceeds from stock option exercises		5,000
Net cash provided by financing activities	3,750,000	29,769,000
Net (decrease) increase in cash, cash equivalents and restricted cash	(16,853,000)	9,989,000
Cash, cash equivalents and restricted cash at:
Beginning of period	19,986,000	8,732,000
End of period	3,133,000	18,721,000
Supplemental cash flow disclosures:
Cash paid for taxes	5,000	2,000
Supplemental noncash investing and financing activities:
Property and equipment additions		119,000
Right-of-use assets obtained with corresponding lease liability	1,877,000
Stock options issued in exchange for accrued liability	107,000
Deemed dividends		$ 4,127,000
Insurance financing	$ 935,000

Description of Business and Bas

Description of Business and Basis of Presentation	9 Months Ended
	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business and Basis of Presentation	1. Description of Business and Basis of Presentation Organization Aridis Pharmaceuticals, Inc. (the “Company” or “we” or “our” or “us”) was established as a California limited liability corporation in 2003. The Company converted to a Delaware C corporation on May 21, 2014. Our principal place of business is in Los Gatos, California. We are a late clinical development - stage biopharmaceutical company focused on developing new breakthrough therapies for infectious diseases and addressing the growing problem of antibiotic resistance. The Company has a diversified portfolio of clinical and pre-clinical stage non-antibiotic anti-infective product candidates that are complimented by a fully human monoclonal antibody discovery platform technology. The Company’s suite of anti-infective monoclonal antibodies offers opportunities to profoundly alter the current trajectory of increasing antibiotic resistance and improve the health outcome of many of the most serious life-threatening infections particularly in hospital settings. Basis of Presentation and Consolidation The accompanying condensed consolidated financial statements include the amounts of the Company and our wholly owned subsidiaries and have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. The condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements. In the opinion of management, the accompanying condensed consolidated financial statements reflect all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the preceding fiscal year included in the Company’s Annual Report on Form 10-K filed with the United States Securities and Exchange Commission (“SEC”) on April 13, 2022. The condensed consolidated financial statements include the accounts of the Company and its two one one COVID-19 The COVID-19 pandemic has caused business disruption globally. The protracted COVID-19 pandemic has continued to cause an impact on patient enrollment globally and the rate of clinical site activation. The extent of the impact of COVID-19 on the Company’s future operational and financial performance will depend on certain developments, including the duration and spread of the pandemic, and impact on the Company’s clinical trials, employees and vendors, all of which are uncertain and cannot be predicted. At this point, the extent to which COVID-19 may impact the Company’s future financial condition or results of operations is uncertain. Going Concern The Company had recurring losses from operations since inception and negative cash flows from operating activities during the three and nine months ended September 30, 2022 and the year ended December 31, 2021. Management expects to incur operating losses and negative cash flows from operations in the foreseeable future as the Company continues its product development programs. The forecasted outflow of cash for at least a one-year period from the expected condensed consolidated financial statement issuance date, is in excess of the cash available on-hand. The Company’s research and development expenses and resulting cash burn during the nine months ended September 30, 2022, were largely due to costs associated with the Phase 3 study of AR-301 for the treatment of ventilator associated pneumonia (“VAP”) caused by the Staphylococcus aureus (S. aureus) S. aureus The Company plans to fund its cash flow needs through current cash on hand and future debt and/or equity financings which we may obtain through one or more public or private equity offerings, debt financings, government or other third-party funding, strategic alliances and licensing or collaboration arrangements. If the Company is unable to obtain funding, the Company could be forced to delay, reduce or eliminate its clinical research and development programs or future commercialization efforts, which could adversely affect its future business prospects and its ability to continue as a going concern. The Company believes that its current available cash and cash equivalents, including cash received in February 2022 from debt proceeds, will not be sufficient to fund its planned expenditures and meet the Company’s obligations for at least the one-year period following its condensed consolidated financial statement issuance date. The accompanying condensed consolidated financial statements have been prepared on a going concern basis that contemplates the realization of assets and discharge of liabilities in their normal course of business. There is substantial doubt about the Company’s ability to continue as a going concern for one year after the date that these condensed consolidated financial statements are issued. These condensed consolidated financial statements do not include any adjustments that might be necessary from the outcome of this uncertainty.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Use of Estimates The preparation of the condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting period. Such estimates include those related to the evaluation of our ability to continue as a going concern, best estimate of standalone selling price of revenue deliverables, useful life of long-lived assets, classification of deferred revenue, income taxes, assumptions used in the Black-Scholes-Merton model to calculate the fair value of stock-based compensation, deferred tax asset valuation allowances, and preclinical study and clinical trial accruals. Actual results could differ from those estimates. Concentrations Credit Risk The Company’s cash and cash equivalents are maintained at financial institutions in the United States of America. Deposits held by these institutions may exceed the amount of insurance provided on such deposits. Customer Risk There was $ 0.4 1.9 27 34 39 100 81 19 76 24 Cash, Cash Equivalents and Restricted Cash The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. Cash and cash equivalents consist primarily of checking account and money market fund account balances. Restricted cash consists of deposits for a letter of credit that the Company has provided to secure its obligations under its facility lease as well as grant funds identified for the specific grant project. The following table provides a reconciliation of cash, cash equivalents and restricted cash within the condensed consolidated balance sheets which, in aggregate, represent the amount reported in the condensed consolidated statements of cash flows (in thousands): Schedule of Cash, Cash Equivalents And Restricted Cash September 30, December 31, 2022 2021 Cash and cash equivalents $ 1,886 $ 18,098 Restricted cash- current 747 1,388 Restricted cash – long-term 500 500 Total cash, cash equivalents and restricted cash $ 3,133 $ 19,986 Accounts Receivable and Allowance for Doubtful Accounts Accounts receivables are recorded at the invoiced amount and do not bear interest. The Company considers the credit worthiness of its customers but does not require collateral in advance of a sale. The Company evaluates collectability and maintains an allowance for doubtful accounts for estimated losses inherent in its accounts receivable portfolio when necessary. The allowance is based on the Company’s best estimate of the amount of losses in the Company’s existing accounts receivable, which is based on customer creditworthiness, facts and circumstances specific to outstanding balances, and payment terms. Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. As of September 30, 2022 and December 31, 2021, there was no Operating Leases The Company determines if an arrangement is or contains a lease at inception by assessing whether the arrangement contains an identified asset and whether it has the right to control the identified asset. Right-of-use (“ROU”) assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Lease liabilities are recognized at the lease commencement date based on the present value of future lease payments over the lease term. ROU assets are based on the measurement of the lease liability and also include any lease payments made prior to or on lease commencement and lease incentives and initial direct costs incurred, as applicable. As the implicit rate in the Company’s leases is generally unknown, the Company used its incremental borrowing rate of 6% based on the information available at the lease commencement date in determining the present value of future lease payments. Lease costs for the Company’s operating leases are recognized on a straight-line basis within operating expenses over the reasonably assured lease term. The Company has elected to not separate lease and non-lease components for any leases within its existing classes of assets and, as a result, accounts for any lease and non-lease components as a single lease component. Prior to adoption of Accounting Standards Codification (“ASC”) 842, Leases as of January 1, 2022, the Company evaluated leases at their inception as either operating or capital leases, and renewal or expansion options, rent holidays, leasehold improvement allowances and other incentives on such lease agreements. The Company recognized operating lease costs on a straight-line basis over the term of the agreement. Property and Equipment Property and equipment are stated at cost less accumulated depreciation. Depreciation and amortization are computed using the straight-line method over the estimated useful lives of the assets, generally between three five years Intangible Assets Intangible assets are recorded at cost and amortized over the estimated useful life of the asset. Intangible assets consist of licenses with various institutions whereby the Company has rights to use intangible property obtained from such institutions. Impairment of Long-Lived Assets The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparison of the carrying amount to the future undiscounted net cash flows which the assets are expected to generate. If such assets are considered to be impaired, the impairment is measured by the excess of the carrying amount of the assets over fair value less the costs to sell the assets, generally determined using the projected discounted future net cash flows arising from the asset. There was no impairments of long-lived assets during the three months ended September 30, 2022 and December 31, 2021. There were no asset impairments during the three months ended September 30, 2022 and there was approximately $ 33,000 in impairments of long-lived assets during the nine months ended September 30, 2022. Revenue Recognition The Company recognizes revenue based on ASC 606, Revenue from Contracts with Customers To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue at a point in time, or over time, as the entity satisfies performance obligations. The Company only applies the five-step model to contracts when it is probable that it will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract, determines those that are performance obligations, and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. As part of the accounting for customer arrangements, the Company must use judgment to determine: a) the number of performance obligations based on the determination under step (ii) above; b) the transaction price under step (iii) above; and c) the standalone selling price for each performance obligation identified in the contract for the allocation of the transaction price in step (iv) above. The Company uses judgment to determine whether milestones or other variable consideration should be included in the transaction price. The transaction price is allocated to each performance obligation on a relative standalone selling price basis. In developing the standalone price for a performance obligation, the Company considers applicable market conditions and relevant entity-specific factors, including factors that were contemplated in negotiating the agreement with the customer and estimated costs. The Company recognizes revenue as or when the performance obligations under the contract are satisfied. The Company receives payments from its customers based on payment schedules established in each contract. The Company records any amounts received prior to satisfying the revenue recognition criteria as deferred revenue on its condensed consolidated balance sheets. Amounts recognized as revenue, but not yet received or invoiced are recorded within other receivables on the condensed consolidated balance sheet. Amounts are recorded as other receivables on the condensed consolidated balance sheet when our right to consideration is unconditional. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the customer and the transfer of a majority of the promised goods or services to the customer will be one year or less. Contract Assets The incremental costs of obtaining a contract under ASC 606 (i.e., costs that would not have been incurred if the contract had not been obtained) are recognized as an asset in the Company’s condensed consolidated balance sheets if the Company expects to recover them (see Note 6). Capitalized costs will be amortized to the respective expenses using a systematic basis that mirrors the pattern in which the Company transfers control of the goods and service to the customer. At each reporting date, the Company determines whether or not the capitalized costs to obtain a contract are impaired by comparing the carrying amount of the asset to the remaining amount of consideration that the Company received and expects to receive less the costs that relate to providing services under the relevant contract. Capitalized contract assets were $ 2.1 no Deferred Revenue Amounts received prior to satisfying the above revenue recognition criteria, or in which the Company has an unconditional right to payment, are recorded as deferred revenue in the Company’s condensed consolidated balance sheets. The Company has estimated the classification between current and noncurrent deferred revenue related to the respective license agreement within its condensed consolidated balance sheets at September 30, 2022 and December 31, 2021 (see Note 6). Research and Development Research and development costs are expensed to operations as incurred. Our research and development expenses consist primarily of: ● salaries and related overhead expenses, which include stock-based compensation and benefits for personnel in research and development functions; ● fees paid to consultants and contract research organizations, or CROs, including in connection with our preclinical studies and clinical trials and other related clinical trial fees, such as for investigator grants, patient screening, laboratory work, clinical trial material management and statistical compilation and analyses; ● costs related to acquiring and manufacturing clinical trial materials; ● costs related to compliance with regulatory requirements; and ● payments related to licensed products and technologies. Costs for certain development activities are recognized based on an evaluation of the progress to completion of specific tasks using information and data provided to us by our vendors and clinical sites. Non-refundable advance payments for goods or services to be received in future periods for use in research and development activities are deferred and capitalized. The capitalized amounts are then expensed as the related goods are delivered or when the services are performed. Capitalized contract assets were $ 2.1 Stock-Based Compensation The Company recognizes compensation expense for all stock-based awards based on the grant-date estimated fair values, which the Company determines using the Black-Scholes-Merton model, on a straight-line basis over the requisite service period for the award. The Company accounts for forfeitures as they occur. The BSM option pricing model incorporates various highly sensitive assumptions, including the fair value of our common stock, expected volatility, expected term and risk-free interest rates. The weighted average expected life of options was calculated using the simplified method as prescribed by the SEC’s Staff Accounting Bulletin, Topic 14 (“SAB Topic 14”). This decision was based on the lack of relevant historical data due to our limited historical experience. In addition, due to our limited historical data, the estimated volatility also reflects the application of SAB Topic 14, incorporating the historical volatility of comparable companies whose stock prices are publicly available. The risk-free interest rate for the periods within the expected term of the option is based on the U.S. Treasury yield in effect at the time of grant. The dividend yield was zero, as we have never declared or paid dividends and have no plans to do so in the foreseeable future. Income Taxes The Company accounts for income taxes under the liability method. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized. The Company assesses all material positions taken in any income tax return, including all significant uncertain positions, in all tax years that are still subject to assessment or challenge by the relevant taxing authorities. Assessing an uncertain tax position begins with the initial determination of the position’s sustainability and is measured at the largest amount of benefit that is greater than 50% likely of being realized upon ultimate settlement. At each balance sheet date, unresolved uncertain tax positions must be reassessed, and the Company will determine whether (i) the factors underlying the sustainability assertion have changed and (ii) the amount of the recognized benefit is still appropriate. The recognition and measurement of tax benefits requires significant judgment. Judgments concerning the recognition and measurement of a tax benefit might change as new information becomes available. The Company’s policy is to recognize interest or penalties related to income tax matters in income tax expense. Comprehensive Loss The Company has no Loss Per Share Basic loss per share is calculated by dividing net loss for the period by the weighted-average number of common shares outstanding during the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common shares and potentially dilutive securities outstanding for the period. There have been no In March 2021 and in August 2021, the Company issued 124,789 634,600 986,000 3.1 For the three and nine months ended September 30, 2022, the number of shares used to compute basic and diluted net loss per share due to the Company’s net loss position was 17.7 12.5 11.3 Schedule of Computation of The Basic And Diluted Net Loss Per Share 2022 2021 2022 2021 Three Months Ended Nine Months Ended September 30, September 30, 2022 2021 2022 2021 (unaudited) (unaudited) (unaudited) (unaudited) Numerator: Net loss available to common stockholders (basic and diluted) $ (8,239 ) $ (24,143 ) $ (23,984 ) $ (37,510 ) Denominator: Weighted-average common shares outstanding used in computing net loss per share available to common stockholders, basic and diluted 17,701,592 12,454,119 17,701,592 11,314,058 Net loss per share to common stockholders, basic and diluted $ (0.47 ) $ (1.94 ) $ (1.35 ) $ (3.32 ) The following potentially dilutive securities were excluded from the computation of diluted net loss per share for the periods presented because including them would have been antidilutive: Schedule of Potentially Dilutive Securities Were Excluded From The Computation of Diluted Net Loss Per Share 2022 2021 Three & Nine Months Ended September 30, 2022 2021 (unaudited) (unaudited) Stock options to purchase common stock 2,118,056 1,739,743 Common stock warrants 3,535,196 4,106,569 Pre-funded common stock warrants — 3,647,556 Potentially dilutive securities excluded from computation of diluted net loss per share 5,653,252 9,493,868 JOBS Act Accounting Election The JOBS Act permits an “emerging growth company” such as us to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies. We are choosing to take advantage of this provision and, as a result, we will adopt the extended transition period available under the JOBS Act until the earlier of the date we (i) are no longer an emerging growth company or (ii) affirmatively and irrevocably opt out of the extended transition period provided under the JOBS Act. Recently Adopted Accounting Pronouncements ASU 2016-02 - Accounting for Lease Obligation (“ASU 2016-02”) In February 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2016-02, Leases (Topic 842). This guidance requires lessees to recognize leases on the balance sheet and disclose key information about leasing arrangements. ASU 2016-02 establishes a right-of-use model (ROU) that requires a lessee to recognize an ROU asset and lease liability on the balance sheet for all leases with a term longer than 12 months. The Company adopted this standard effective January 1, 2022, as required, retrospectively through a cumulative effect adjustment. The new standard provides a number of optional practical expedients in transition. The Company elected the “package of practical expedients,” which permits the Company not to reassess, under ASU 2016-02, prior conclusions about lease identification, lease classification and initial direct costs. The new standard also provides practical expedients for an entity’s ongoing accounting. The Company elected to utilize the short-term lease recognition exemption for all leases that qualify. This means, for those short-term leases that qualify, the Company will not recognize ROU assets or lease liabilities. The Company also elected to separate lease and non-lease components for facility leases. Adoption of this guidance resulted in the recognition of lease liabilities of $ 2.3 1.9 ASU 2020-06 - Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”) In August 2020, the FASB issued ASU 2020-06, which simplifies the guidance on the issuer’s accounting for convertible debt instruments by removing the separation models for (1) convertible debt with a cash conversion feature and (2) convertible instruments with a beneficial conversion feature. As a result, entities will not separately present in equity an embedded conversion feature in such debt and will account for a convertible debt instrument wholly as debt, unless certain other conditions are met. The elimination of these models will reduce reported interest expense and increase reported net income for entities that have issued a convertible instrument that is within the scope of ASU 2020-06. Also, ASU 2020-06 requires the application of the if-converted method for calculating diluted earnings per share and treasury stock method will be no longer available. ASU 2020-06 is applicable for fiscal years beginning after December 15, 2021, with early adoption permitted no earlier than fiscal years beginning after December 15, 2020. Adoption of ASU 2020-06 as of January 1, 2022 did not have an impact on the Company’s condensed consolidated financial statements and disclosures. Accounting Standards Update 2016-13 In June 2016, the FASB issued ASU 2016-13, “ Financial Instruments- Credit Losses (ASC 326) Accounting Standards Update 2019-12 In December 2019, the FASB issued ASU 2019-12, “ Simplifying the Accounting for Income Taxes (ASC 740)

Fair Value Disclosure

Fair Value Disclosure	9 Months Ended
	Sep. 30, 2022
Fair Value Disclosures [Abstract]
Fair Value Disclosure	3. Fair Value Disclosure Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy defines a three-level valuation hierarchy for disclosure of fair value measurements as follows: Level 1 Unadjusted quoted prices in active markets for identical assets or liabilities; Level 2 Inputs other than quoted prices included within Level 1 that are observable, unadjusted quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and Level 3 Unobservable inputs that are supported by little or no market activity for the related assets or liabilities. The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The Company has elected the fair value option for calculating the value of its Notes Payable and are classified as Level 2. The carrying value of the Company’s cash and cash equivalents, restricted cash, prepaid assets and other current assets, other assets, accounts payable, and accrued liabilities approximate fair value due to the short-term nature of these items.

Balance Sheet Components

Balance Sheet Components	9 Months Ended
	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Balance Sheet Components	4. Balance Sheet Components Property and Equipment, net Property and equipment, net consist of the following (in thousands): Schedule of Property And Equipment, Net September 30, December 31, 2022 2021 (unaudited) Lab equipment $ 2,391 $ 2,390 Computer equipment and software — 25 Leasehold improvements 527 527 Total property and equipment 2,918 2,942 Less: Accumulated depreciation (1,944 ) (1,585 ) Property and equipment, net $ 974 $ 1,357 Depreciation expense was approximately $ 123,000 93,000 383,000 274,000 Intangible Assets, net Intangible assets, net consist of the following (in thousands): Schedule of Intangible Assets, Net September 30, December 31, 2022 2021 (unaudited) Licenses $ 81 $ 81 Less: Accumulated amortization (63 ) (59 ) Intangible assets, net $ 18 $ 22 Amortization expense was approximately $ 1,000 4,000 Licenses Broad Institute of MIT and Harvard — Non-Exclusive Manufacturing License Agreement In January 2021, we entered into a non-exclusive manufacturing licensing agreement with the Broad Institute of MIT and Harvard (the “Broad Institute”) to make and manufacture CRISPR Modified Cell Lines, CRISPR Modified Animals and CRISPR Modified Plants. These license rights permit the non-exclusive use of the CRISPR Technology for the creation of and improvement of yield from protein and mAb production cell lines, which is one of the core components of the ʎPEX TM Pursuant to this agreement, the Company is obligated to pay to the Broad Institute an issue fee of $ 25,000 50,000 100,000 7 0.5 MedImmune Limited — License Agreement In July 2021, the Company executed a license agreement effective July 12, 2021 and entered into an amendment to the license agreement on August 9, 2021 (collectively the “MedImmune License Agreement”) with MedImmune Limited (“MedImmune”), pursuant to which MedImmune granted the Company an exclusive worldwide license for the development and commercialization of suvratoxumab, a Phase 3 ready fully human monoclonal antibody targeting the S. 5.0 5.0 884,956 6.5 As additional consideration, the Company will pay MedImmune milestone payments upon the achievement of certain regulatory approvals, for one licensed product, up to a total aggregate amount of $ 30.0 85.0 no 12.5 15 Accrued Liabilities Accrued liabilities consist of the following (in thousands): Schedule of Accrued Liabilities September 30, December 31, 2022 2021 (unaudited) Research and development services $ 7,866 $ 5,939 Payroll related expenses 605 416 Professional services and other 23 109 Accrued liabilities $ 8,494 $ 6,464

Equity Method Investment

Equity Method Investment	9 Months Ended
	Sep. 30, 2022
Equity Method Investments and Joint Ventures [Abstract]
Equity Method Investment	5. Equity Method Investment On February 11, 2018, the Company entered into a joint venture agreement (the “JV Agreement”) with Shenzhen Hepalink Pharmaceutical Group Co., Ltd., a related party, principal shareholder of the Company, and a Chinese entity (“Hepalink”), to develop and commercialize products for infectious diseases. Under the terms of the JV Agreement, the Company contributed $ 1.0 49 On August 6, 2018, the Company entered into an amendment to the JV Agreement with Hepalink whereby the Company agreed to additionally contribute an exclusive, revocable, and royalty-free right and license to its AR-105 product candidate in the Territory. Pursuant to the JV Agreement and the amendment, Hepalink initially owns 51 7.2 10.8 The Company evaluated the accounting for the JV Agreement entered into, noting that it did not meet the accounting definition of a joint venture and instead meets the definition of a variable interest entity. The Company concluded that it is not the primary beneficiary of the JV Entity and therefore is not required to consolidate the entity. This conclusion was based on the fact that the equity-at-risk is insufficient to support operations without additional investment and that the Company does not hold decision-making power over activities that significantly impact the JV Entity’s operations. The Company accounted for its investment in the JV Entity as an equity method investment. The Company recorded the equity method investment at $ 1.0 0 0

Development and License Agreeme

Development and License Agreements	9 Months Ended
	Sep. 30, 2022
Development And License Agreements
Development and License Agreements	6. Development and License Agreements Agreement with Innovative Medicines Initiative Joint Undertaking In March 2021, the Company entered into an agreement (the IMI JU Agreement) with the Innovative Medicines Initiative (IMI) funded consortium COMBACTE-NET to collaborate with other participants in a joint undertaking (the IMI JU) to combat bacterial resistance in Europe. The project facilitates a pan-European clinical trial network to test antibiotics and other drugs to prevent and treat various infections. This project commenced on January 1, 2013 with an initial duration of seven years. It has since been extended to October 31, 2023. The project has 46 participants including European Federation of Pharmaceutical Industries and Associations (EFPIA) companies, universities, research organizations, public bodies, non-profit groups, subject matter experts, and third parties. The Company’s primary role in the project is to help lead a Phase 3, randomized, double-blind, placebo-controlled trial to evaluate efficacy of suvratoxumab in the prevention of S. aureus The academic COMBACTE-NET consortium partners initially pay for all costs incurred at EU clinical sites and subsequently bills the Company for 25% of such costs. Specifically, we are billed for 25% of eligible costs during the entire fiscal year six to seven months following the fiscal year. The work at these sites is performed entirely by third-party subcontractors. As such, we reimburse the 25% at the passed-through invoice amounts. There is no reimbursement for costs incurred at non-EU sites. Under the IMI JU Agreement, the Company will own all results, findings, and intellectual property generated by the project and is entitled to receive any benefits these items bring. As such, these costs are deemed research and development expenditures. Considering our obligation to repay a portion of costs incurred, we determined this agreement is under the scope of ASC Subtopic 730-20, Research and Development Arrangements. Further, as the parties in the IMI JU Agreement are active participants and are exposed to significant risks and rewards dependent on the commercial success of the research, this agreement is also under the scope of ASC Topic 808, Collaborative Arrangements. For research and development costs incurred at non-EU sites, we recognize these expenses as incurred. There were no such expenses incurred for the three and nine months ended September 30, 2021. We recognized research and development expense of $ 1.7 4.6 For research and development costs incurred at EU sites, we recognize a liability for the 25% of these costs we are obligated to repay. This amount reflects gross expenditures incurred net of contributed services to be received from the IMI JU. There were no such expenses incurred for the three and nine months ended September 30, 2021. Research and development expense of approximately $ 1.3 2.5 1.0 1.9 0.6 0 In-kind contributions we make to the program will be expensed as R&D at their fair value when made. If the fair value of an in-kind contribution we make to the IMI JU differs from its carrying amount, we will recognize a gain or loss on disposition. No Cystic Fibrosis Foundation Development Agreement In December 2016, the Company received an award from the Cystic Fibrosis Foundation (“CFF”), which was executed under the Development Program Letter Agreement (the “CFF Agreement”), for approximately $ 2.9 200,000 7.5 As of the adoption date of ASC 606 on January 1, 2019 (the “Adoption Date”), the Company identified the following promises with regards to the clinical research activities under the CFF Agreement that represent an initial contract of: a) Phase 1 single ascending dose (“SAD”) clinical trial, which consists of the satisfied development-based milestones and one development-based milestone in progress which was accounted for as a single performance obligation; and contingent promises of: b) Phase 1 multiple ascending dose (“MAD”) clinical trial, which consists of one development-based milestone that had not yet been started, and c) Phase 2a clinical trial, which consists of four development-based milestones that had not yet been started. Of these promises, the Phase 1 SAD clinical trial was determined to be a distinct performance obligation as of the Adoption Date. For the clinical research activities related to the Phase 1 MAD clinical trial and the Phase 2a clinical trial that had not yet been started, the Company was contingently obligated to perform these clinical research activities only after the previous milestones, which achievement was uncertain, had been met. The clinical research activities related to the Phase 1 MAD clinical trial and the Phase 2a clinical trial that had not been started were evaluated to determine if they should be considered variable consideration or contingent promises akin to optional purchases under ASC 606. The Company concluded that these two promises that have not been started are contingent promises because there is substantive uncertainty about the contingent event occurring (i.e. milestones being achieved) and the contingent event requires additional distinct services and incremental payments from the CFF. The Company determined that these contingent promises did not provide the CFF with any material rights. The Phase 1 MAD clinical trial and the Phase 2a clinical trial will be accounted for as separate contracts at the time the Company is obligated to perform the underlying clinical research activities. The Company determined that the consideration for the Phase 1 SAD clinical trial contract included several development-based milestones, which had been achieved as of the Adoption Date, totaling approximately $ 1.7 1.0 1.0 The Company determined the consideration for the Phase 2a clinical trial contract totals approximately $ 3.8 2.0 The milestones under the CFF Agreement are development-based milestones related to pre-clinical and clinical research activities and the realization of or recognition of revenue associated with the milestones as determined by the completion of the milestones and, if applicable, review and approval of the achievement by the CFF. Each development-based milestone payment has specific criteria that needs to be met, some examples of which include, the completion of certain study activities and approval to move to the next activity. At every reporting period, the Company evaluates the individual facts and circumstances of the development-based milestone to assess whether the revenue attributable to the development-based milestone in progress should be constrained. The constraint assessment by the Company includes an analysis of the key judgements and considerations used for each milestone which include, but are not limited to, the nature and amount of work to be performed, if the work is subject to the approval of the CFF, clinical data and uncertainty with regards to the results of the clinical studies, and the probability of successful clinical studies. The constraint will be removed once the Company achieves the development-based milestone or has determined that there is probable completion of the development-based milestone, and it has also concluded that it is not probable that revenue recognized attributable to the development-based milestone will result in a significant reversal of revenue in the future. The Company determined that the clinical research activities under the CFF Agreement should be recognized over time by calculating the amount of revenue to recognize in any given period by accumulating the total related costs incurred for the respective clinical research activities related to that distinct performance obligation using the input method (cost-to-cost) and applies that percentage of completion to the transaction price at each reporting period. The Company believes this method best depicts the transfer of control to the customer, which occurs as the costs related to the clinical research activities are incurred. For the three and nine months ended September 30, 2022, the Company recognized revenue from the CFF Agreement of approximately $( 83,000 732,000 For the three and nine months ended September 30, 2021, the Company recognized revenue of approximately $ 417,000 Gates Foundation Grant Agreement On October 15, 2021, the Company entered into an agreement with the Bill and Melinda Gates Foundation (“Gates Foundation” or “BMGF”) by executing a grant agreement identified as Investment ID INV-033376 (“Grant Agreement”). The goal of the Grant Agreement is to develop durable approaches to block the infection and transmission of pathogens. For providing research and development services under the Grant Agreement, the Gates Foundation has agreed to compensate the Company $ 1.93 Under the Grant Agreement, the Gates Foundation made an upfront payment of $ 1.93 The Company will conduct research and development services up until the proof-of-concept study is completed, at which point the Gates Foundation will determine whether to approve further grant funding for transmission studies or end the study in which case the Company will no longer provide any significant goods or services. The Company will partner with three main subcontractors to deliver the scope of work described in the investment document. The Grant Agreement is considered within the scope of ASC 606 as the parties have a customer/vendor relationship and are not exposed equally to the risks and rewards of the research and development services contemplated in the Grant Agreement. The Company identified the following promises under the Agreement: 1) research and development services, 2) global access commitment, 3) humanitarian license, 4) publication if requested by the Gates Foundation, and 5) intellectual property reporting upon request. The Company determined that these promises are not distinct from each other, and therefore represent one performance obligation. Since the Company is required to update the Gates Foundation on technical progress during each stage of the Funded Development, the ability to access research and development results represents the Gates Foundation’s consumption of the benefits from the Company’s research and development activities. As such, research and development services revenue are recognized over time. At each reporting period, the amount of revenue to recognize is calculated using the input method (cost-to-cost), by comparing cumulative costs incurred to the total estimated costs to perform the research and development services and applying that percentage of completion to the transaction price. The Company believes this method best depicts the transfer of control to the customer, which occurs as the costs related to the research and development services are incurred. For the three and nine months ended September 30, 2022, the Company recognized revenue of approximately $ 388,000 640,000 747,000 Serum License Agreement In July 2019, the Company and Serum International B.V. (“SIBV”), an affiliate of Serum Institute of India Private Limited, entered into an option agreement which granted SIBV the option to license multiple programs from the Company and access the Company’s MabIgX® platform technology for asset identification and selection. The Company received an upfront cash payment of $ 5 801,820 10 In September 2019, the Company and Serum AMR Products (“SAMR”), a party under common ownership of SIBV, entered into a License, Development and Commercialization Agreement (the “License Agreement”). Pursuant to the License Agreement, the Company granted to SAMR exclusive licenses, and rights to sublicense, certain patent rights and technology related know-how to the Company’s products AR-301, AR-105, AR-101 (i.e. exclusive rights to, among other things, develop, distribute, market, promote, sell, import and otherwise commercialize) in (a) the country of India, and (b) all other countries of the world except the USA, Canada, EU Territory, UK, China, Australia, South Korea, Brazil, New Zealand, and Japan (products AR-105 and AR-101 countries do not exclude South Korea and Brazil) (the “Limited Territory”); and AR-201 (i.e. exclusive rights to, among other things, develop, manufacture, make, distribute, market, promote, sell, import and otherwise commercialize) in all countries of the world except China, Hong Kong, Macau and Taiwan (the “Worldwide Territory”) (the “licenses and know-how”). Further, the License Agreement grants SAMR an option for the Company to provide research services using its MabIgX® platform technology for the identification of up to five (5) candidates including product development of these identified candidates and an exclusive license to develop, manufacture, make, distribute, market, promote, sell, import and otherwise commercialize these development products in the Worldwide Territory (the “research and development option”). Pursuant to the License Agreement the Company will provide development support related to the licensed products above in order to assist SAMR in its efforts to develop, receive regulatory approval, and manufacture and sell the licensed products in SAMR’s authorized territories which will be performed under the direction of a Joint Steering Committee (“JSC”) which the Company will participate in (collectively, “development support services”). In addition, under the License Agreement, SAMR was granted an exclusive manufacturing license option as the initial license granted above for AR-301, AR-105 and AR-101 does not allow for manufacturing. This manufacturing option provides incremental rights related to these products beyond what is granted as part of the licensing discussed above (the “manufacturing rights option”). If this option is exercised, after SAMR has met certain requirements to exercise the option as defined in the License Agreement, it would provide for an exclusive license for use by SAMR to manufacture and supply the products for SAMR’s own use in the Limited Territory and to manufacture and supply these products to the Company, or their affiliates, for the Company’s use outside the Limited Territory. Should SAMR exercise the development and research option or the manufacturing rights option discussed above, SAMR and the Company shall negotiate in good faith the economic terms around these arrangements. If a third party sublicensee of AR-301, AR-105 and AR-101 wishes to manufacture these products by itself for the territory for which it has a license from the Company, then the Company shall have the right to buy back the manufacturing rights for all territories outside of the Limited Territory by paying to SAMR $ 5 Under the License Agreement, the Company received upfront payments totaling $ 15 5 42.5 Given the equity investment by SIBV was negotiated in conjunction with the option agreement, which resulted in the execution of the License Agreement, all arrangements were evaluated as a single agreement and amounts were allocated to the elements of the arrangement based on their fair value. The Company recorded approximately $ 5.0 5.4 441,000 4.6 19.6 15.0 4.6 The License Agreement is determined to be within the scope of ASC 606, as the transaction represents a contract with a customer where the participants function in a customer/vendor relationship and are not exposed equally to the risks and rewards of the activities contemplated under the License Agreement. Using the concepts of ASC 606, the Company identified the following performance obligations under the License Agreement: 1) the transfer of licenses of the intellectual property for AR-301, AR-101, AR-105 and AR-201, inclusive of the related technology know-how conveyance (referred to as the license and know-how above); and 2) the Company to deliver ongoing development support services related to the licensed products and the Company’s participation in the JSC (referred to as the development support services above); and identified the following material promises under the License Agreement: 3) SAMR was granted a research and development option of up to five identified product candidates for the Company to perform including specific development services (the research and development option referred to above); and 4) SAMR was granted an exclusive manufacturing license option which would provide for incremental manufacturing rights related to AR-301, AR-105 and AR-101 beyond what is granted in the License Agreement (the manufacturing rights option referred to above). The Company concluded that the performance obligations and material promises identified are separate and distinct from each other. The Company is also entitled to additional payments from SAMR of up to $ 42.5 The Company determined that the transaction price under the License Agreement was $ 19.6 15.0 4.6 19.6 14.5 79,000 892,000 4.1 The Company determined that the intellectual property licensed under the License Agreement represents functional intellectual property and it has significant standalone functionality and therefore should be recognized at a point in time upon satisfying the performance obligations. The Company will satisfy the performance obligations upon transfer of the licenses and know-how to SAMR and expects to satisfy these performance obligations by the end of 2022. The Company determined that no performance obligations or material promises were satisfied as of September 30, 2022, and therefore, no 18.9 18.7 737,000 854,000 2.1 2.0 2.0 78,000 96,000 K ermode Licensing and Product Discovery Agreement In February 2021, the Company entered into an out-licensing and product discovery agreement with Kermode Biotechnologies, Inc. (“Kermode”) and a statement of work (the “Kermode Agreement”). Under the terms of this agreement, Kermode will fund for one year the discovery of product candidates for African Swine Fever Virus (“ASFV”) with an option to include the discovery of product candidates for swine influenza virus (“SIV”). Kermode also received exclusive rights to all mAbs and vaccines discovered for veterinary uses and rights to a non-exclusive license to use the Company’s ʎPEX technology platform for further development activities. The Company retained exclusive rights to mAbs and vaccines discovered for human uses. In March 2021, the Company received a non-refundable upfront payment of $ 500,000 250,000 The Kermode Agreement is within the scope of ASC 606 as the parties have a customer/vendor relationship and are not exposed equally to the risks and rewards of the activities contemplated in the Kermode Agreement. The Company identified the following promises under the Kermode Agreement: 1) research and development services, and 2) license rights of the ʎPEX Platform and mAbs and vaccines (“Program IP”). The Company determined that these promises are not distinct from each other, and therefore represent one performance obligation. As of September 30, 2022, the transaction price of the Kermode Agreement was $ 1,000,000 500,000 500,000 The Company determined that the one performance obligation under the Kermode Agreement should be recognized over time. At each reporting period, the amount of revenue to recognize will be calculated using the input method (cost-to-cost), by comparing cumulative costs incurred to the total estimated costs to perform all four phases of the research and development activities, and applying that percentage of completion to the transaction price. The Company believes this method best depicts the transfer of control to the customer, which occurs as the costs related to the research and development activities are incurred. For the three and nine months ended September 30, 2022, the Company recognized approximately $ 93,000 506,000 29,000 98,000 131,000

Paycheck Protection Program Loa

Paycheck Protection Program Loan	9 Months Ended
	Sep. 30, 2022
Paycheck Protection Program Loan
Paycheck Protection Program Loan	7. Paycheck Protection Program Loan The Company applied for and received a loan, which is in the form of a note dated May 1, 2020, from Silicon Valley Bank (“SVB”) in the aggregate amount of approximately $ 715,000 In May 2021, the Company received confirmation that the PPP Loan was forgiven by the SBA and was legally released from its financial obligation by the lender, SVB. As such, for the three and nine months ended September 30, 2021, the Company recognized in its condensed consolidated statement of operations a gain on extinguishment of PPP Loan of approximately $ 722,000 715,000 7,000 no

Notes Payable

Notes Payable	9 Months Ended
	Sep. 30, 2022
Debt Disclosure [Abstract]
Notes Payable	8. Notes Payable Note Purchase Agreement On November 23, 2021, the Company entered into an agreement (“Note Purchase Agreement”) with Streeterville Capital, LLC (Lender), pursuant to which it issued to the Lender a secured promissory note (Note) in the aggregate principal amount of $ 5,250,000 250,000 6 November 23, 2023 450,000 5,250,000 February 21, 2024 495,000 450,000 45,000 Payments of each redemption amount must be made in cash. Pursuant to the Note, the Company can defer all redemption payments that the Lender could otherwise elect to make during any calendar month on three (3) separate occasions by providing written notice to Lender at least three (3) trading days prior to the first day of each such calendar month for which it wishes to defer redemptions for that month. In the event the Company elects to defer, the aggregate principal amount plus accrued but unpaid interest (Outstanding Amount) shall automatically be increased by (a) 0.5 1 1.5 105 107.5 110 On September 30, 2022, the Company signed an amendment to promissory note #2. Subject to certain provisions and so long as no Event of Default has occurred, then in addition to the three (3) deferral rights previously available, the Company shall have the right to exercise additional monthly deferrals until March 31, 2023 (each, an “Additional Deferral”). Each time Borrower exercises an Additional Deferral the Outstanding Balance will automatically be increased by 1.5%. Pursuant to the Note Purchase Agreement, the Company is subject to certain covenants, including the obligations to: (i) timely file all reports required to be filed under Sections 13 or 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and not terminate its status as an issuer required to file reports under the Exchange Act; (ii) maintain listing of its common stock on a securities exchange; and (iii) avoid trading in its common stock from being suspended, halted, chilled, frozen or otherwise ceased. The Note is secured by the Company’s MabIgX assets. The Company elected to apply the fair value option to the measurement of this Note. The total initial fair value at issuance was $ 5,250,000 for each Note. The Company remeasured the fair value as of September 30, 2022 and recognized an expense of approximately $ 823,000 and $ 1,212,000 for the three and nine month periods as the fair value of note had increased, which included approximately $ 220,000 and $ 247,000 for the three and nine month periods related to deferral fees. Additionally, the Company separated the short-term and long-term components of the Notes. Due to the redemption right of the Lender, a portion of the notes payable could be required to be settled within one year of the balance sheet date. Amounts required to be settled within one year of the balance sheet date should be recorded as current liabilities on the accompanying condensed consolidated balance sheets. The current portion of notes payable was not reflected in the Company’s December 31, 2021 consolidated financial statements and March 31, 2022 and June 30, 2022 interim financial statements, but was corrected during the quarter ended September 30, 2022. Had it been properly recorded during the periods ended December 31, 2021, March 31, 2022 and June 30, 2022, the effect on the Company’s consolidated financial statements would have been as follows: Schedule of Change in Notes Payable As reported If Corrected Difference December 31, 2021 Notes payable current - 1,800,000 (1,800,000 ) Notes payable long term 5,282,000 3,482,000 1,800,000 March 31, 2022 Notes payable current - 5,400,000 (5,400,000 ) Notes payable long term 10,648,000 5,248,000 5,400,000 June 30, 2022 Notes payable current - 7,580,000 (7,580,000 ) Notes payable long term 10,922,000 3,342,000 7,580,000 The company performed a thorough assessment to determine the significance of the error to the prior periods and concluded that it was not material to the Company’s financial position, results of operations or cash flows for the periods ended December 31, 2021, March 31, 2022 and June 30, 2022. The fair value measurement includes interest, at the stated rate, and this separate amount is not reflected in the condensed consolidated statement of operations. The Company has recorded a liability of approximately $ 7,795,000 3,499,000 11,294,000 for both Notes, as of September 30, 2022. Fair value of notes payable (in thousands): Schedule of Fair Value of Notes Payable Balance as of December 31, 2021 $ 5,282 Addition of notes payable 5,000 Payment (450 ) Original issuance discount 250 Change in fair value of notes payable 1,212 Balance as of September 30, 2022 $ 11,294 Insurance Financing The Company obtained financing for certain Director & Officer liability insurance policy premiums. The agreement assigns First Insurance Funding (Lender) a first priority lien on and security interest in the financed policies and any additional premium required in the financed policies including (a) all returned or unearned premiums, (b) all additional cash contributions or collateral amounts assessed by the insurance companies in relation to the financed policies and financed by Lender, (c) any credits generated by the financed policies, (d) dividend payments, and (e) loss payments which reduce unearned premiums. If any circumstances exist in which premiums related to any Financed Policy could become fully earned in the event of loss, Lender shall be named a loss-payee with respect to such policy. The total premiums, taxes and fees financed is approximately $ 915,000 5.129 831,000 696,000

Warrants

Warrants	9 Months Ended
	Sep. 30, 2022
Warrants
Warrants	9. Warrants In August 2021, the Company entered into a Securities Purchase Agreement (the “August 2021 Securities Purchase Agreement”) with an institutional investor, pursuant to which the Company agreed to offer, issue and sell to this investor, in a registered direct offering, 1,300,000 3,647,556 2,473,778 5.053 5.052 0.001 25.0 22.6 Each Warrant is exercisable for one 5.00 seven years 4.99 9.99 one 0.001 4.99 9.99% The Company measured the fair value of the Common Stock and Pre-Funded Warrants based on the Company’s closing stock price on the date the August 2021 Purchase Agreement was entered into and the fair value of the Warrants was based upon a BSM valuation model. The BSM valuation model used the following assumptions: expected term of seven years 97 0.96 0 22.6 4.4 12.2 In December 2021, all of the Pre-Funded Warrants were exercised. A total of 3,647,556 4,000

Common Stock

Common Stock	9 Months Ended
	Sep. 30, 2022
Equity [Abstract]
Common Stock	10. Common Stock As of September 30, 2022 (unaudited), the Company had reserved the following common stock for future issuance: Schedule of Common Stock Reserved for Future Issuance Shares reserved for exercise of outstanding warrants to purchase common stock 3,535,196 Shares reserved for exercise of outstanding options to purchase common stock 2,118,056 Shares reserved for issuance of future options 765,502 Total 6,418,754 Securities Purchase Agreement In March 2021, the Company entered into a Securities Purchase Agreement (the “March 2021 Securities Purchase Agreement”) with certain institutional and individual investors (the “Purchasers”), pursuant to which the Company agreed to offer, issue and sell to the Purchasers, in a registered direct offering, an aggregate of 1,037,405 0.0001 7.0 6.4 In October 2020, shares of Common Stock were sold in a registered direct offering in which each share contains a price based anti-dilution rights. If the Company issues additional securities at a purchase price less than the purchase price paid by these respective holders, the Company shall issue additional common shares equal to the difference of the number of common shares that each respective shareholder would have received if they paid the subsequent lower price, and the number of shares each respective shareholder originally received. As a result of the March 2021 registered direct offering price per share being less than the October 2020 registered direct offering price per share, the Company was obligated to issue an additional 124,789 124,789 986,000 MedImmune Limited License Agreement Effective July 12, 2021, the Company entered into the MedImmune License Agreement, pursuant to which MedImmune granted the Company an exclusive worldwide license for the development and commercialization of suvratoxumab, a Phase 3 ready fully human monoclonal antibody targeting S. , 884,956 884,956 6.5 6.5 August 2021 Securities Purchase Agreement In August 2021, the Company entered into a Securities Purchase Agreement (the “August 2021 Securities Purchase Agreement”) with an institutional investor, pursuant to which the Company agreed to offer, issue and sell to this investor, in a registered direct offering, 1,300,000 3,647,556 2,473,778 5.053 5.052 0.001 25.0 22.6 As a result of this registered direct offering price per share being less than the October 2020 and March 2021 registered direct offerings price per share, the Company was obligated to issue an additional 634,600 634,600 3.1 ATM Agreement On January 19, 2022, the Company entered into an At-the-Market Sales Agreement (“Sales Agreement”) with Virtu Americas LLC (“Virtu”), as sales agent. Pursuant to the terms of the Sales Agreement, the Company may issue and sell from time-to-time shares of its common stock, par value $ 0.0001 25.0 Under the Sales Agreement, Shares will be offered and sold pursuant to the Company’s shelf registration statement on Form S-3 (File No. 333-233601) filed with the Securities and Exchange Commission (the “SEC”) on September 3, 2019, declared effective by the SEC on September 5, 2019. In addition, under the Sales Agreement, sales of Shares may be made by any method permitted by law deemed to be an “at the market offering” as defined in Rule 415(a)(4) under the Securities Act of 1933, as amended. The Company will pay Virtu a commission rate of up to 3.0 During the three and nine-month period ended September 30, 2022, the Company had not sold any shares of common stock under the ATM Sales Agreement. The ATM Sales Agreement facility currently cannot be used without the Company updating certain required conditions that are expired. The Company presently has no plans to update such required conditions.

Stock-Based Compensation

Stock-Based Compensation	9 Months Ended
	Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]
Stock-Based Compensation	11. Stock-Based Compensation Equity Incentive Plan In May 2014, the Company adopted and the shareholders approved the 2014 Equity Incentive Plan (the 2014 Plan). Under the 2014 Plan, 233,722 10 110 In June 2020, the adoption of an amendment to the 2014 Plan to eliminate the evergreen provision and set the number of shares of common stock reserved for issuance thereunder to 2,183,692 In June 2022, the shareholder approved an additional 750,000 Stock Options The number of shares, terms, and vesting periods are determined by the Company’s Board of Directors or a committee thereof on an option-by-option basis. Options generally vest ratably over service periods of up to four years ten years Stock option activity for the nine months ended September 30, 2022 is represented in the following table: Share-based Compensation, Stock Options, Activity Options Outstanding Weighted- Shares Available Number of Average for Grant Shares Exercise Price Balances at December 31, 2021 228,099 1,905,459 $ 8.48 Options granted (85,635 ) 85,635 $ 1.92 Options cancelled 42,064 (42,064 ) $ 5.80 Balances at March 31, 2022 184,528 1,949,030 $ 8.24 Additional shares reserved 750,000 — $ — Options granted (258,934 ) 258,934 $ 1.06 Options cancelled 102,249 (102,249 ) $ 6.88 Balances at June 30, 2022 777,843 2,105,715 $ 7.42 Options granted (35,000 ) 35,000 $ 1.91 Options cancelled 22,659 (22,659 ) $ 5.61 Balances at September 30, 2022 765,502 2,118,056 $ 7.35 The Company estimated the fair value of options using the BSM option valuation model. The fair value of options is being amortized on a straight-line basis over the requisite service period of the awards. The fair value of the options granted during the three and nine months ended September 30, 2022 and the three and nine months ended September 30, 2021 were estimated using the following assumptions: Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions Three Months Ended Nine Months Ended September 30, September 30, 2022 2021 2022 2021 Expected term (in years) 6.00 — 6.00 6.00 Expected volatility 99 % — 99 114 % 99 100 % Risk-free interest-rate 3.45 % — 1.72 3.45 % 0.75 1.14 % Dividend yield 0 % — 0 % 0 % During the three and nine months ended September 30, 2022, the Company granted options to purchase 35,000 379,569 1.53 1.00 224,140 5.04 There were no no 1,559 5,000 Stock-Based Compensation The following table presents stock-based compensation expense related to stock options (in thousands): Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs 2022 2021 2022 2021 Three Months Ended Nine Months Ended September 30, September 30, 2022 2021 2022 2021 (unaudited) (unaudited) (unaudited) (unaudited) Research and development $ 159 $ 170 $ 385 $ 502 General and administrative 190 410 776 1,198 Total $ 349 $ 580 $ 1,161 $ 1,700 As of September 30, 2022, total unrecognized stock-based compensation expenses related to unvested stock options was approximately $ 1.4 2.67

Related Parties

Related Parties	9 Months Ended
	Sep. 30, 2022
Related Party Transactions [Abstract]
Related Parties	12. Related Parties Joint Venture On February 11, 2018, the Company entered into a Joint Venture (“JV”) Agreement with Hepalink which is a related party and principal shareholder in the Company, pursuant to which the Company formed a JV Entity for developing and commercializing products for infectious diseases in the greater China territories. It was agreed by the parties that the Company shall be reimbursed for certain legal and contract manufacturing expenses related to the clinical drug supply for a Phase 3 clinical study of AR-301 and the clinical drug supply for a clinical study of AR-105. For the three months ended September 30, 2022 and 2021, the Company recorded approximately $ 0 14,000 0 60,000 13,000 28,000 Serum International B.V. In July 2019, the Company issued 801,820 10 The Company determined that no performance obligations or material promises were satisfied as of September 30, 2022, and therefore, no revenue related to the License Agreement was recognized for the three and nine months ended September 30, 2022 and, 2021. The Company has recorded contract liabilities resulting from the License Agreement of approximately $ 18.9 18.7 737,000 854,000 2.1 2.0 2.0 78,000 90,000

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	13. Commitments and Contingencies Facility Lease The Company determines if an arrangement is a finance lease, operating lease or short-term lease at inception, or as applicable, and accounts for the arrangement under the relevant accounting literature. Currently, the Company is only party to a non-cancelable office space operating lease. Under the relevant guidance, the Company recognizes operating lease ROU assets and liabilities based on the present value of the future minimum lease payments over the lease term at the commencement date, using the Company’s assumed incremental borrowing rate of 6 In October 2020, the Company entered into a new lease agreement (the “Lease Agreement”) with Boccardo Corporation (the “Landlord”) pursuant to which the Company leased approximately 15,129 378,000 five three 500,000 As of January 1, 2022, the Company adopted ASC 842, Leases 6 1.9 2.3 Schedule of Operating Lease Assets And Liabilities ROU assets, net $ 1,532 Current portion of lease liabilities (included in current liabilities) 526 Lease liabilities, less current portion 1,430 Total lease liabilities $ 1,956 The future minimum lease payments for the new facility as of September 30, 2022 are as follows (in thousands): Schedule of Future Minimum Rental Payments for Operating Leases Period ending: Three months ending December 31, 2022 $ 153 Year ending December 31, 2023 628 Year ending December 31, 2024 646 Year ending December 31, 2025 666 Thereafter 57 Future minimum lease payments 2,150 Interest remaining (194 ) Total $ 1,956 Indemnification In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications. The Company’s exposure under these agreements is unknown because it involves claims that may be made against the Company in the future but have not yet been made. To date, the Company has not paid any claims or been required to defend any action related to its indemnification obligations. However, the Company may incur charges in the future as a result of these indemnification obligations. License Agreements The Company has entered into various collaboration and licensing agreements that provide it with access to certain technology and patent rights. Under the terms of the agreements, the Company may be required to make milestone payments upon achievement of certain development and regulatory activities. None of these events occurred as of September 30, 2022. Contingencies From time to time, the Company may have certain contingent liabilities that arise in the ordinary course of its business activities. The Company accrues a liability for such matters when it is probable that a potential loss will be incurred and such amount can be reasonably estimated. As of September 30, 2022 and December 31, 2021, no accruals have been made related to commitments and contingencies. From time to time, the Company may be involved in various legal proceedings, claims and litigation arising in the ordinary course of business. See below Legal Proceedings ongoing at December 31, 2021, and as of September 30, 2022. Legal Proceedings A complaint was filed in February 2020 in the New York State Supreme Court against the Company by an investor who invested in the Company’s preferred stock in July 2017 prior to the Company’s IPO in August 2018. The complaint alleges, among other things, that the Company breached its contract and fiduciary duty, by not issuing additional securities to the investor as a result of the Company’s IPO. The plaintiff is asking for approximately $ 277,000 531,686.85 The Company submitted an amended complaint in Superior Court of the State of California, County of Santa Clara, against our former landlord on February 4, 2022, asserting claims for breach of contract, breach of the covenant of good faith and fair dealing, wrongful eviction/constructive eviction and unjust enrichment and violation of the unfair competition law. The claims arise from rent increases and the termination of the tenancy that we allege were not permitted by the agreement with the landlord. We seek to recover rent paid under protest, our deposit, moving and relocation expenses and consequential damages arising from disruption to our operations. The landlord has filed a cross-complaint for damage to property and attorneys’ fees. The Company believes that the cross- complaint is without merit and intends to defend against it. The Company accrues a liability for such matters when it is probable that potential loss will be incurred and such amount can be reasonably estimated. As of September 30, 2022 and December 31, 2021, no Grant Revenue The Company receives various grants that are subject to audit by the grantors or their representatives. Such audits could result in requests for reimbursement for expenditures disallowed under the terms of the grant. As of September 30, 2022 and December 31, 2021, management believes that the Company has complied with all of the required grant terms. There are no grant audits currently in process. Cystic Fibrosis Foundation Agreement In December 2016, the Company received an award for up to $ 2.9 7.5 No In the event that development efforts are successful and the Company commercializes a drug from these related development efforts, the Company will be subject to paying to CFF a one-time amount over time equal to nine five ninety days 15 In the event that the Company licenses rights to the product in the field to a third-party, sells the product, or consummates a change of control transaction prior to the first commercial sale, the Company shall pay to CFF an amount equal to 15 In the event that the development efforts are delayed, which result from events within the Company’s control, for more than one hundred eighty (180) consecutive days at any time before the first commercialization of the drug from the related development efforts, the CFF may provide an interruption notice to the Company, or in lieu of the interruption license, pay to the CFF an amount greater than two times the award received plus interest up to the time of such election. The Company then has thirty (30) days to respond to such notice. If the Company does not respond within thirty (30) days, an interruption license shall be effective. The interruption license to the CFF is an exclusive, worldwide license under the development program technology to manufacture, have manufactured, license, use, sell, offer to sell, and support the product in the field and includes financial conditions for both parties. None of these events have occurred as of September 30, 2022 and December 31, 2021. Kermode Agreement In February 2021, the Company entered into the Kermode Agreement, in which the Company received an upfront payment of $ 500,000 250,000

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2022
Subsequent Events [Abstract]
Subsequent Events	14. Subsequent Events In October, 2022 the Company entered into a Securities Purchase Agreement with an institutional investor, pursuant to which it agreed to offer, issue and sell to this investor, in a registered direct offering, 1,800,000 5,407,208 1.11 1.109 7,207,208 1.11 8.0 7.8 In addition, upon the closing of the offerings, in consideration for the Purchaser’s participation in the offerings the Company has agreed to amend, the Purchaser’s existing warrants to purchase up to 2,473,778 5.00 2.00

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Use of Estimates	Use of Estimates The preparation of the condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting period. Such estimates include those related to the evaluation of our ability to continue as a going concern, best estimate of standalone selling price of revenue deliverables, useful life of long-lived assets, classification of deferred revenue, income taxes, assumptions used in the Black-Scholes-Merton model to calculate the fair value of stock-based compensation, deferred tax asset valuation allowances, and preclinical study and clinical trial accruals. Actual results could differ from those estimates.
Concentrations	Concentrations Credit Risk The Company’s cash and cash equivalents are maintained at financial institutions in the United States of America. Deposits held by these institutions may exceed the amount of insurance provided on such deposits. Customer Risk There was $ 0.4 1.9 27 34 39 100 81 19 76 24
Cash, Cash Equivalents and Restricted Cash	Cash, Cash Equivalents and Restricted Cash The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. Cash and cash equivalents consist primarily of checking account and money market fund account balances. Restricted cash consists of deposits for a letter of credit that the Company has provided to secure its obligations under its facility lease as well as grant funds identified for the specific grant project. The following table provides a reconciliation of cash, cash equivalents and restricted cash within the condensed consolidated balance sheets which, in aggregate, represent the amount reported in the condensed consolidated statements of cash flows (in thousands): Schedule of Cash, Cash Equivalents And Restricted Cash September 30, December 31, 2022 2021 Cash and cash equivalents $ 1,886 $ 18,098 Restricted cash- current 747 1,388 Restricted cash – long-term 500 500 Total cash, cash equivalents and restricted cash $ 3,133 $ 19,986
Accounts Receivable and Allowance for Doubtful Accounts	Accounts Receivable and Allowance for Doubtful Accounts Accounts receivables are recorded at the invoiced amount and do not bear interest. The Company considers the credit worthiness of its customers but does not require collateral in advance of a sale. The Company evaluates collectability and maintains an allowance for doubtful accounts for estimated losses inherent in its accounts receivable portfolio when necessary. The allowance is based on the Company’s best estimate of the amount of losses in the Company’s existing accounts receivable, which is based on customer creditworthiness, facts and circumstances specific to outstanding balances, and payment terms. Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. As of September 30, 2022 and December 31, 2021, there was no
Operating Leases	Operating Leases The Company determines if an arrangement is or contains a lease at inception by assessing whether the arrangement contains an identified asset and whether it has the right to control the identified asset. Right-of-use (“ROU”) assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Lease liabilities are recognized at the lease commencement date based on the present value of future lease payments over the lease term. ROU assets are based on the measurement of the lease liability and also include any lease payments made prior to or on lease commencement and lease incentives and initial direct costs incurred, as applicable. As the implicit rate in the Company’s leases is generally unknown, the Company used its incremental borrowing rate of 6% based on the information available at the lease commencement date in determining the present value of future lease payments. Lease costs for the Company’s operating leases are recognized on a straight-line basis within operating expenses over the reasonably assured lease term. The Company has elected to not separate lease and non-lease components for any leases within its existing classes of assets and, as a result, accounts for any lease and non-lease components as a single lease component. Prior to adoption of Accounting Standards Codification (“ASC”) 842, Leases as of January 1, 2022, the Company evaluated leases at their inception as either operating or capital leases, and renewal or expansion options, rent holidays, leasehold improvement allowances and other incentives on such lease agreements. The Company recognized operating lease costs on a straight-line basis over the term of the agreement.
Property and Equipment	Property and Equipment Property and equipment are stated at cost less accumulated depreciation. Depreciation and amortization are computed using the straight-line method over the estimated useful lives of the assets, generally between three five years
Intangible Assets	Intangible Assets Intangible assets are recorded at cost and amortized over the estimated useful life of the asset. Intangible assets consist of licenses with various institutions whereby the Company has rights to use intangible property obtained from such institutions.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparison of the carrying amount to the future undiscounted net cash flows which the assets are expected to generate. If such assets are considered to be impaired, the impairment is measured by the excess of the carrying amount of the assets over fair value less the costs to sell the assets, generally determined using the projected discounted future net cash flows arising from the asset. There was no impairments of long-lived assets during the three months ended September 30, 2022 and December 31, 2021. There were no asset impairments during the three months ended September 30, 2022 and there was approximately $ 33,000 in impairments of long-lived assets during the nine months ended September 30, 2022.
Revenue Recognition	Revenue Recognition The Company recognizes revenue based on ASC 606, Revenue from Contracts with Customers To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue at a point in time, or over time, as the entity satisfies performance obligations. The Company only applies the five-step model to contracts when it is probable that it will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract, determines those that are performance obligations, and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. As part of the accounting for customer arrangements, the Company must use judgment to determine: a) the number of performance obligations based on the determination under step (ii) above; b) the transaction price under step (iii) above; and c) the standalone selling price for each performance obligation identified in the contract for the allocation of the transaction price in step (iv) above. The Company uses judgment to determine whether milestones or other variable consideration should be included in the transaction price. The transaction price is allocated to each performance obligation on a relative standalone selling price basis. In developing the standalone price for a performance obligation, the Company considers applicable market conditions and relevant entity-specific factors, including factors that were contemplated in negotiating the agreement with the customer and estimated costs. The Company recognizes revenue as or when the performance obligations under the contract are satisfied. The Company receives payments from its customers based on payment schedules established in each contract. The Company records any amounts received prior to satisfying the revenue recognition criteria as deferred revenue on its condensed consolidated balance sheets. Amounts recognized as revenue, but not yet received or invoiced are recorded within other receivables on the condensed consolidated balance sheet. Amounts are recorded as other receivables on the condensed consolidated balance sheet when our right to consideration is unconditional. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the customer and the transfer of a majority of the promised goods or services to the customer will be one year or less. Contract Assets The incremental costs of obtaining a contract under ASC 606 (i.e., costs that would not have been incurred if the contract had not been obtained) are recognized as an asset in the Company’s condensed consolidated balance sheets if the Company expects to recover them (see Note 6). Capitalized costs will be amortized to the respective expenses using a systematic basis that mirrors the pattern in which the Company transfers control of the goods and service to the customer. At each reporting date, the Company determines whether or not the capitalized costs to obtain a contract are impaired by comparing the carrying amount of the asset to the remaining amount of consideration that the Company received and expects to receive less the costs that relate to providing services under the relevant contract. Capitalized contract assets were $ 2.1 no Deferred Revenue Amounts received prior to satisfying the above revenue recognition criteria, or in which the Company has an unconditional right to payment, are recorded as deferred revenue in the Company’s condensed consolidated balance sheets. The Company has estimated the classification between current and noncurrent deferred revenue related to the respective license agreement within its condensed consolidated balance sheets at September 30, 2022 and December 31, 2021 (see Note 6).
Research and Development	Research and Development Research and development costs are expensed to operations as incurred. Our research and development expenses consist primarily of: ● salaries and related overhead expenses, which include stock-based compensation and benefits for personnel in research and development functions; ● fees paid to consultants and contract research organizations, or CROs, including in connection with our preclinical studies and clinical trials and other related clinical trial fees, such as for investigator grants, patient screening, laboratory work, clinical trial material management and statistical compilation and analyses; ● costs related to acquiring and manufacturing clinical trial materials; ● costs related to compliance with regulatory requirements; and ● payments related to licensed products and technologies. Costs for certain development activities are recognized based on an evaluation of the progress to completion of specific tasks using information and data provided to us by our vendors and clinical sites. Non-refundable advance payments for goods or services to be received in future periods for use in research and development activities are deferred and capitalized. The capitalized amounts are then expensed as the related goods are delivered or when the services are performed. Capitalized contract assets were $ 2.1
Stock-Based Compensation	Stock-Based Compensation The Company recognizes compensation expense for all stock-based awards based on the grant-date estimated fair values, which the Company determines using the Black-Scholes-Merton model, on a straight-line basis over the requisite service period for the award. The Company accounts for forfeitures as they occur. The BSM option pricing model incorporates various highly sensitive assumptions, including the fair value of our common stock, expected volatility, expected term and risk-free interest rates. The weighted average expected life of options was calculated using the simplified method as prescribed by the SEC’s Staff Accounting Bulletin, Topic 14 (“SAB Topic 14”). This decision was based on the lack of relevant historical data due to our limited historical experience. In addition, due to our limited historical data, the estimated volatility also reflects the application of SAB Topic 14, incorporating the historical volatility of comparable companies whose stock prices are publicly available. The risk-free interest rate for the periods within the expected term of the option is based on the U.S. Treasury yield in effect at the time of grant. The dividend yield was zero, as we have never declared or paid dividends and have no plans to do so in the foreseeable future.
Income Taxes	Income Taxes The Company accounts for income taxes under the liability method. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized. The Company assesses all material positions taken in any income tax return, including all significant uncertain positions, in all tax years that are still subject to assessment or challenge by the relevant taxing authorities. Assessing an uncertain tax position begins with the initial determination of the position’s sustainability and is measured at the largest amount of benefit that is greater than 50% likely of being realized upon ultimate settlement. At each balance sheet date, unresolved uncertain tax positions must be reassessed, and the Company will determine whether (i) the factors underlying the sustainability assertion have changed and (ii) the amount of the recognized benefit is still appropriate. The recognition and measurement of tax benefits requires significant judgment. Judgments concerning the recognition and measurement of a tax benefit might change as new information becomes available. The Company’s policy is to recognize interest or penalties related to income tax matters in income tax expense.
Comprehensive Loss	Comprehensive Loss The Company has no
Loss Per Share	Loss Per Share Basic loss per share is calculated by dividing net loss for the period by the weighted-average number of common shares outstanding during the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common shares and potentially dilutive securities outstanding for the period. There have been no In March 2021 and in August 2021, the Company issued 124,789 634,600 986,000 3.1 For the three and nine months ended September 30, 2022, the number of shares used to compute basic and diluted net loss per share due to the Company’s net loss position was 17.7 12.5 11.3 Schedule of Computation of The Basic And Diluted Net Loss Per Share 2022 2021 2022 2021 Three Months Ended Nine Months Ended September 30, September 30, 2022 2021 2022 2021 (unaudited) (unaudited) (unaudited) (unaudited) Numerator: Net loss available to common stockholders (basic and diluted) $ (8,239 ) $ (24,143 ) $ (23,984 ) $ (37,510 ) Denominator: Weighted-average common shares outstanding used in computing net loss per share available to common stockholders, basic and diluted 17,701,592 12,454,119 17,701,592 11,314,058 Net loss per share to common stockholders, basic and diluted $ (0.47 ) $ (1.94 ) $ (1.35 ) $ (3.32 ) The following potentially dilutive securities were excluded from the computation of diluted net loss per share for the periods presented because including them would have been antidilutive: Schedule of Potentially Dilutive Securities Were Excluded From The Computation of Diluted Net Loss Per Share 2022 2021 Three & Nine Months Ended September 30, 2022 2021 (unaudited) (unaudited) Stock options to purchase common stock 2,118,056 1,739,743 Common stock warrants 3,535,196 4,106,569 Pre-funded common stock warrants — 3,647,556 Potentially dilutive securities excluded from computation of diluted net loss per share 5,653,252 9,493,868
JOBS Act Accounting Election	JOBS Act Accounting Election The JOBS Act permits an “emerging growth company” such as us to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies. We are choosing to take advantage of this provision and, as a result, we will adopt the extended transition period available under the JOBS Act until the earlier of the date we (i) are no longer an emerging growth company or (ii) affirmatively and irrevocably opt out of the extended transition period provided under the JOBS Act.
Recently Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements ASU 2016-02 - Accounting for Lease Obligation (“ASU 2016-02”) In February 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2016-02, Leases (Topic 842). This guidance requires lessees to recognize leases on the balance sheet and disclose key information about leasing arrangements. ASU 2016-02 establishes a right-of-use model (ROU) that requires a lessee to recognize an ROU asset and lease liability on the balance sheet for all leases with a term longer than 12 months. The Company adopted this standard effective January 1, 2022, as required, retrospectively through a cumulative effect adjustment. The new standard provides a number of optional practical expedients in transition. The Company elected the “package of practical expedients,” which permits the Company not to reassess, under ASU 2016-02, prior conclusions about lease identification, lease classification and initial direct costs. The new standard also provides practical expedients for an entity’s ongoing accounting. The Company elected to utilize the short-term lease recognition exemption for all leases that qualify. This means, for those short-term leases that qualify, the Company will not recognize ROU assets or lease liabilities. The Company also elected to separate lease and non-lease components for facility leases. Adoption of this guidance resulted in the recognition of lease liabilities of $ 2.3 1.9 ASU 2020-06 - Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”) In August 2020, the FASB issued ASU 2020-06, which simplifies the guidance on the issuer’s accounting for convertible debt instruments by removing the separation models for (1) convertible debt with a cash conversion feature and (2) convertible instruments with a beneficial conversion feature. As a result, entities will not separately present in equity an embedded conversion feature in such debt and will account for a convertible debt instrument wholly as debt, unless certain other conditions are met. The elimination of these models will reduce reported interest expense and increase reported net income for entities that have issued a convertible instrument that is within the scope of ASU 2020-06. Also, ASU 2020-06 requires the application of the if-converted method for calculating diluted earnings per share and treasury stock method will be no longer available. ASU 2020-06 is applicable for fiscal years beginning after December 15, 2021, with early adoption permitted no earlier than fiscal years beginning after December 15, 2020. Adoption of ASU 2020-06 as of January 1, 2022 did not have an impact on the Company’s condensed consolidated financial statements and disclosures. Accounting Standards Update 2016-13 In June 2016, the FASB issued ASU 2016-13, “ Financial Instruments- Credit Losses (ASC 326) Accounting Standards Update 2019-12 In December 2019, the FASB issued ASU 2019-12, “ Simplifying the Accounting for Income Taxes (ASC 740)

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Schedule of Cash, Cash Equivalents And Restricted Cash	The following table provides a reconciliation of cash, cash equivalents and restricted cash within the condensed consolidated balance sheets which, in aggregate, represent the amount reported in the condensed consolidated statements of cash flows (in thousands): Schedule of Cash, Cash Equivalents And Restricted Cash September 30, December 31, 2022 2021 Cash and cash equivalents $ 1,886 $ 18,098 Restricted cash- current 747 1,388 Restricted cash – long-term 500 500 Total cash, cash equivalents and restricted cash $ 3,133 $ 19,986
Schedule of Computation of The Basic And Diluted Net Loss Per Share	Schedule of Computation of The Basic And Diluted Net Loss Per Share 2022 2021 2022 2021 Three Months Ended Nine Months Ended September 30, September 30, 2022 2021 2022 2021 (unaudited) (unaudited) (unaudited) (unaudited) Numerator: Net loss available to common stockholders (basic and diluted) $ (8,239 ) $ (24,143 ) $ (23,984 ) $ (37,510 ) Denominator: Weighted-average common shares outstanding used in computing net loss per share available to common stockholders, basic and diluted 17,701,592 12,454,119 17,701,592 11,314,058 Net loss per share to common stockholders, basic and diluted $ (0.47 ) $ (1.94 ) $ (1.35 ) $ (3.32 )
Schedule of Potentially Dilutive Securities Were Excluded From The Computation of Diluted Net Loss Per Share	The following potentially dilutive securities were excluded from the computation of diluted net loss per share for the periods presented because including them would have been antidilutive: Schedule of Potentially Dilutive Securities Were Excluded From The Computation of Diluted Net Loss Per Share 2022 2021 Three & Nine Months Ended September 30, 2022 2021 (unaudited) (unaudited) Stock options to purchase common stock 2,118,056 1,739,743 Common stock warrants 3,535,196 4,106,569 Pre-funded common stock warrants — 3,647,556 Potentially dilutive securities excluded from computation of diluted net loss per share 5,653,252 9,493,868

Balance Sheet Components (Table

Balance Sheet Components (Tables)	9 Months Ended
	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Property And Equipment, Net	Property and equipment, net consist of the following (in thousands): Schedule of Property And Equipment, Net September 30, December 31, 2022 2021 (unaudited) Lab equipment $ 2,391 $ 2,390 Computer equipment and software — 25 Leasehold improvements 527 527 Total property and equipment 2,918 2,942 Less: Accumulated depreciation (1,944 ) (1,585 ) Property and equipment, net $ 974 $ 1,357
Schedule of Intangible Assets, Net	Intangible assets, net consist of the following (in thousands): Schedule of Intangible Assets, Net September 30, December 31, 2022 2021 (unaudited) Licenses $ 81 $ 81 Less: Accumulated amortization (63 ) (59 ) Intangible assets, net $ 18 $ 22
Schedule of Accrued Liabilities	Accrued liabilities consist of the following (in thousands): Schedule of Accrued Liabilities September 30, December 31, 2022 2021 (unaudited) Research and development services $ 7,866 $ 5,939 Payroll related expenses 605 416 Professional services and other 23 109 Accrued liabilities $ 8,494 $ 6,464

Notes Payable (Tables)

Notes Payable (Tables)	9 Months Ended
	Sep. 30, 2022
Debt Disclosure [Abstract]
Schedule of Change in Notes Payable	Schedule of Change in Notes Payable As reported If Corrected Difference December 31, 2021 Notes payable current - 1,800,000 (1,800,000 ) Notes payable long term 5,282,000 3,482,000 1,800,000 March 31, 2022 Notes payable current - 5,400,000 (5,400,000 ) Notes payable long term 10,648,000 5,248,000 5,400,000 June 30, 2022 Notes payable current - 7,580,000 (7,580,000 ) Notes payable long term 10,922,000 3,342,000 7,580,000
Schedule of Fair Value of Notes Payable	Fair value of notes payable (in thousands): Schedule of Fair Value of Notes Payable Balance as of December 31, 2021 $ 5,282 Addition of notes payable 5,000 Payment (450 ) Original issuance discount 250 Change in fair value of notes payable 1,212 Balance as of September 30, 2022 $ 11,294

Common Stock (Tables)

Common Stock (Tables)	9 Months Ended
	Sep. 30, 2022
Equity [Abstract]
Schedule of Common Stock Reserved for Future Issuance	As of September 30, 2022 (unaudited), the Company had reserved the following common stock for future issuance: Schedule of Common Stock Reserved for Future Issuance Shares reserved for exercise of outstanding warrants to purchase common stock 3,535,196 Shares reserved for exercise of outstanding options to purchase common stock 2,118,056 Shares reserved for issuance of future options 765,502 Total 6,418,754

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]
Share-based Compensation, Stock Options, Activity	Stock option activity for the nine months ended September 30, 2022 is represented in the following table: Share-based Compensation, Stock Options, Activity Options Outstanding Weighted- Shares Available Number of Average for Grant Shares Exercise Price Balances at December 31, 2021 228,099 1,905,459 $ 8.48 Options granted (85,635 ) 85,635 $ 1.92 Options cancelled 42,064 (42,064 ) $ 5.80 Balances at March 31, 2022 184,528 1,949,030 $ 8.24 Additional shares reserved 750,000 — $ — Options granted (258,934 ) 258,934 $ 1.06 Options cancelled 102,249 (102,249 ) $ 6.88 Balances at June 30, 2022 777,843 2,105,715 $ 7.42 Options granted (35,000 ) 35,000 $ 1.91 Options cancelled 22,659 (22,659 ) $ 5.61 Balances at September 30, 2022 765,502 2,118,056 $ 7.35
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions	Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions Three Months Ended Nine Months Ended September 30, September 30, 2022 2021 2022 2021 Expected term (in years) 6.00 — 6.00 6.00 Expected volatility 99 % — 99 114 % 99 100 % Risk-free interest-rate 3.45 % — 1.72 3.45 % 0.75 1.14 % Dividend yield 0 % — 0 % 0 %
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs	The following table presents stock-based compensation expense related to stock options (in thousands): Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs 2022 2021 2022 2021 Three Months Ended Nine Months Ended September 30, September 30, 2022 2021 2022 2021 (unaudited) (unaudited) (unaudited) (unaudited) Research and development $ 159 $ 170 $ 385 $ 502 General and administrative 190 410 776 1,198 Total $ 349 $ 580 $ 1,161 $ 1,700

Commitments and Contingencies (

Commitments and Contingencies (Tables)	9 Months Ended
	Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Schedule of Operating Lease Assets And Liabilities	Schedule of Operating Lease Assets And Liabilities ROU assets, net $ 1,532 Current portion of lease liabilities (included in current liabilities) 526 Lease liabilities, less current portion 1,430 Total lease liabilities $ 1,956
Schedule of Future Minimum Rental Payments for Operating Leases	The future minimum lease payments for the new facility as of September 30, 2022 are as follows (in thousands): Schedule of Future Minimum Rental Payments for Operating Leases Period ending: Three months ending December 31, 2022 $ 153 Year ending December 31, 2023 628 Year ending December 31, 2024 646 Year ending December 31, 2025 666 Thereafter 57 Future minimum lease payments 2,150 Interest remaining (194 ) Total $ 1,956

Description of Business and B_2

Description of Business and Basis of Presentation (Details Narrative)	9 Months Ended
	Sep. 30, 2022 Segment Subsidiary
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Wholly owned subsidiaries | Subsidiary	2
Operating segments	1
Reporting segments	1

Schedule of Cash, Cash Equivale

Schedule of Cash, Cash Equivalents And Restricted Cash (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021	Sep. 30, 2021	Dec. 31, 2020
Accounting Policies [Abstract]
Cash and cash equivalents	$ 1,886	$ 18,098
Restricted cash- current	747	1,388
Restricted cash – long-term	500	500
Total cash, cash equivalents and restricted cash	$ 3,133	$ 19,986	$ 18,721	$ 8,732

Schedule of Computation of The

Schedule of Computation of The Basic And Diluted Net Loss Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Accounting Policies [Abstract]
Net loss available to common stockholders (basic and diluted)	$ (8,239)	$ (24,143)	$ (23,984)	$ (37,510)
Weighted-average common shares outstanding used in computing net loss per share available to common stockholders, basic and diluted	17,701,592	12,454,119	17,701,592	11,314,058
Net loss per share to common stockholders, basic and diluted	$ (0.47)	$ (1.94)	$ (1.35)	$ (3.32)

Schedule of Potentially Dilutiv

Schedule of Potentially Dilutive Securities Were Excluded From The Computation of Diluted Net Loss Per Share (Details) - shares	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Potentially dilutive securities excluded from computation of diluted net loss per share	5,653,252	9,493,868
Common Stock [Member] | Share-Based Payment Arrangement, Option [Member]
Potentially dilutive securities excluded from computation of diluted net loss per share	2,118,056	1,739,743
Common Stock [Member] | Warrant [Member]
Potentially dilutive securities excluded from computation of diluted net loss per share	3,535,196	4,106,569
Common Stock [Member] | Prefunded Warrants [Member]
Potentially dilutive securities excluded from computation of diluted net loss per share		3,647,556

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	1 Months Ended		3 Months Ended		9 Months Ended
	Aug. 31, 2021	Mar. 31, 2021	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Jan. 01, 2022	Dec. 31, 2021
Product Information [Line Items]
Revenue			$ 399,000	$ 515,000	$ 1,878,000	$ 548,000
Allowance for doubtful accounts			0		0			$ 0
Asset Impairment Charges					33,000
Capitalized contract assets			2,100,000		2,100,000			2,100,000
Capitalized contract cost, amortization			0	$ 0	0	$ 0
Capitalized contract asset			$ 2,100,000		2,100,000			$ 2,100,000
Comprehensive income or loss					$ 0
Deemed dividends	634,600	124,789			0
Weighted-average, net loss per share			17,701,592	12,454,119	17,701,592	11,314,058
Recognition of lease liabilities							$ 2,300,000
Recognition of lease assets							$ 1,900,000
Common Stock [Member]
Product Information [Line Items]
Deemed dividends				634,600		759,389
Fair value of dividend shares issued to common stockholders				$ 986,000		$ 3,100,000
Minimum [Member]
Product Information [Line Items]
Estimated useful life					3 years
Maximum [Member]
Product Information [Line Items]
Estimated useful life					5 years
Three Customer [Member] | Revenue from Contract with Customer Benchmark [Member] | Customer Concentration Risk [Member]
Product Information [Line Items]
Revenue			$ 400,000		$ 1,900,000
Customer One [Member] | Revenue from Contract with Customer Benchmark [Member] | Customer Concentration Risk [Member]
Product Information [Line Items]
Concentration risk percentage				81%	27%	76%
Customer Two [Member] | Revenue from Contract with Customer Benchmark [Member] | Customer Concentration Risk [Member]
Product Information [Line Items]
Concentration risk percentage					34%
Customer Three [Member] | Revenue from Contract with Customer Benchmark [Member] | Customer Concentration Risk [Member]
Product Information [Line Items]
Concentration risk percentage					39%
Customer [Member] | Revenue from Contract with Customer Benchmark [Member] | Customer Concentration Risk [Member]
Product Information [Line Items]
Concentration risk percentage				19%	100%	24%

Schedule of Property And Equipm

Schedule of Property And Equipment, Net (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Total property and equipment	$ 2,918	$ 2,942
Less: Accumulated depreciation	(1,944)	(1,585)
Property and equipment, net	974	1,357
Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment	2,391	2,390
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment		25
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment	$ 527	$ 527

Schedule of Intangible Assets,

Schedule of Intangible Assets, Net (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Licenses	$ 81	$ 81
Less: Accumulated amortization	(63)	(59)
Intangible assets, net	$ 18	$ 22

Schedule of Accrued Liabilities

Schedule of Accrued Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Research and development services	$ 7,866	$ 5,939
Payroll related expenses	605	416
Professional services and other	23	109
Accrued liabilities	$ 8,494	$ 6,464

Balance Sheet Components (Detai

Balance Sheet Components (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Jul. 31, 2021
Depreciation expense	$ 123,000	$ 93,000	$ 383,000	$ 274,000
Amortization expense	1,000	1,000	$ 4,000	4,000
Number of common stock issued		$ 23,294,000		$ 29,711,000
Medimmune Customer [Member] | Minimum [Member]
Percentage for royalty payments based on net sales volume			12.50%
Medimmune Customer [Member] | Maximum [Member]
Percentage for royalty payments based on net sales volume			15%
Medimmune Limited [Member] | Medimmune License Agreement [Member]
Contractual liability						$ 5,000,000
Issuance of common stock, shares			884,956
Medimmune Limited [Member] | Medimmune License Agreement [Member] | One Licensed Product [Member]
Total aggregate milestone payments	30,000,000		$ 30,000,000
Medimmune Limited [Member] | Medimmune License Agreement [Member] | Research and Development Expense [Member]
Number of common stock issued					$ 6,500,000
Total aggregate milestone payments	0		0
Medimmune Limited [Member] | Medimmune License Agreement [Member] | Sales [Member]
Total aggregate milestone payments	$ 85,000,000		85,000,000
Medimmune Limited [Member] | Medimmune License Agreement [Member] | Other Liabilities [Member]
Minimum research funding agreed to provide					$ 5,000,000
Broad Institute of Mit and Harvard [Member]
Issue fee			$ 25,000
Royalty expense as a percentage of service income			7%
Percentage of end product net sales			0.50%
Broad Institute of Mit and Harvard [Member] | 2022 [Member]
Annual license maintenance fee			$ 50,000
Broad Institute of Mit and Harvard [Member] | 2023 [Member]
Annual license maintenance fee			$ 100,000

Equity Method Investment (Detai

Equity Method Investment (Details Narrative) - USD ($)	Sep. 30, 2022	Dec. 31, 2021	Aug. 06, 2018	Feb. 11, 2018
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. [Member]
Schedule of Equity Method Investments [Line Items]
Percentage of ownership interest			51%	49%
Equity method investment, minimum future investment obligation			$ 10,800,000
Joint Venture Agreement [Member] | Shenzhen Hepalink Pharmaceutical Group Co., Ltd. [Member]
Schedule of Equity Method Investments [Line Items]
Minimum research funding agreed to provide			7,200,000	$ 1,000,000
Equity method investment	$ 0	$ 0	$ 1,000,000
Carryover basis of license contributed	$ 0

Development and License Agree_2

Development and License Agreements (Details Narrative) - USD ($)		1 Months Ended						3 Months Ended		9 Months Ended		12 Months Ended
	Oct. 15, 2021	Dec. 31, 2021	Mar. 31, 2021	Sep. 30, 2019	Jul. 31, 2019	Nov. 30, 2018	Dec. 31, 2016	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Dec. 31, 2019	Jun. 30, 2020	Mar. 31, 2019
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Development and license agreements description										The academic COMBACTE-NET consortium partners initially pay for all costs incurred at EU clinical sites and subsequently bills the Company for 25% of such costs. Specifically, we are billed for 25% of eligible costs during the entire fiscal year six to seven months following the fiscal year. The work at these sites is performed entirely by third-party subcontractors. As such, we reimburse the 25% at the passed-through invoice amounts. There is no reimbursement for costs incurred at non-EU sites.
Research and development expense								$ 6,118,000	$ 19,842,000	$ 18,916,000	$ 29,370,000
Liabilities		$ 39,906,000						47,943,000		47,943,000		$ 39,906,000
Gain or loss on disposition										0
Revenue								399,000	515,000	1,878,000	548,000
Deferred revenue		20,838,000						20,386,000		20,386,000		20,838,000
Issuance of common stock, value									23,294,000		29,711,000
Deferred revenue, non-current		913,000						737,000		737,000		913,000
Capitalized contract cost, Current		1,967,000						1,986,000		1,986,000		1,967,000
Capitalized contract cost, Noncurrent		96,000						78,000		78,000		96,000
Cystic Fibrosis Foundation Development Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Amount of award						$ 7,500,000	$ 2,900,000
Award, upfront payment received							$ 200,000
Revenue								83,000	417,000	732,000	417,000
Grants Foundation Grant Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue recognized								388,000		640,000
Deferred revenue								747,000		747,000
Grants Foundation Grant Agreement [Member] | Bill and Melinda Gates Foundation [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Amount of compensation	$ 1,930,000
Upfront payment received	$ 1,930,000
Serum License Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upfront payment received				$ 15,000,000	$ 5,000,000
Buy back manufacturing rights					$ 5,000,000
Maximum additional payments entitled										42,500,000		19,600,000
Fair value of net proceeds													$ 5,000,000
Fair value of gross proceeds													5,400,000
Issuance costs from equity allocation													$ 441,000
Deferred revenue from equity allocation		4,600,000						4,600,000		4,600,000		4,600,000
Contractual liability		19,600,000						19,600,000		19,600,000		19,600,000
Deferred revenue based on upfront payments		15,000,000						15,000,000		15,000,000		15,000,000
Serum License Agreement [Member] | License and Service [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Contractual liability		14,500,000										14,500,000
Serum License Agreement [Member] | Development Support Services [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Contractual liability		79,000										79,000
Serum License Agreement [Member] | Research and Development Option [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Contractual liability		892,000										892,000
Serum License Agreement [Member] | Manufacturing Rights Option [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Contractual liability		4,100,000										4,100,000
Serum License Agreement [Member] | License [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Contractual liability		18,700,000						18,900,000		18,900,000		18,700,000
Revenue								0		0
Deferred revenue, non-current		854,000						737,000		737,000		854,000
Capitalized contract costs		2,100,000										2,100,000
Capitalized contract cost, Current		2,000,000						2,000,000		2,000,000		2,000,000
Capitalized contract cost, Noncurrent		96,000						78,000		78,000		96,000
Serum License Agreement [Member] | Maximum [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Maximum additional payments entitled										42,500,000
Kermode Licensing and Product Discovery Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue recognized								93,000	$ 98,000	506,000	$ 131,000
Deferred revenue								29,000		29,000
Maximum additional payments entitled		250,000
Gross transaction price								1,000,000		1,000,000
Kermode Licensing and Product Discovery Agreement [Member] | Research and Development Option [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Nonrefundable upfront payment										500,000
Kermode Licensing and Product Discovery Agreement [Member] | License [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upfront payment received			$ 500,000
Non-EUSites [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and development expense								1,700,000		4,600,000
EU Site [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Research and development expense								1,300,000		2,500,000
Gross expenses contributed services amount								1,000,000		1,900,000
Liabilities		$ 0						$ 600,000		600,000		$ 0
Several Development Based Milestones [Member] | Cystic Fibrosis Foundation Development Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Probable transaction price performance obligations															$ 1,700,000
One Development Based Milestone in Progress [Member] | Cystic Fibrosis Foundation Development Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Amount of probable variable consideration															$ 1,000,000
Amount of achieved consideration														$ 1,000,000
Four Develpoment Based Milestones [Member] | Cystic Fibrosis Foundation Development Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Amount of variable consideration										3,800,000
Two Develpoment Based Milestones [Member] | Cystic Fibrosis Foundation Development Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Amount of variable consideration										$ 2,000,000
Restricted Stock [Member] | Serum License Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Issuance of common stock, shares					801,820
Issuance of common stock, value					$ 10,000,000

Paycheck Protection Program L_2

Paycheck Protection Program Loan (Details Narrative) - USD ($)	9 Months Ended
	Sep. 30, 2022	Dec. 31, 2021	May 01, 2020
Short-Term Debt [Line Items]
Liabilities	$ 47,943,000	$ 39,906,000
Paycheck Protection Program Loan [Member]
Short-Term Debt [Line Items]
Principal amount	715,000		$ 715,000
Gain on extinguishment of PPP Loan	722,000
Accrued interest	7,000
Liabilities	$ 0

Schedule of Change in Notes Pay

Schedule of Change in Notes Payable (Details) - USD ($)	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2021
Notes Payable, Current	$ 831,000			$ 696,000
Notes Payable, Noncurrent	$ 3,499,000			5,282,000
Previously Reported [Member]
Notes Payable, Current
Notes Payable, Noncurrent		10,922,000	10,648,000	5,282,000
Revision of Prior Period, Reclassification, Adjustment [Member]
Notes Payable, Current		7,580,000	5,400,000	1,800,000
Notes Payable, Noncurrent		3,342,000	5,248,000	3,482,000
Revision of Prior Period, Adjustment [Member]
Notes Payable, Current		(7,580,000)	(5,400,000)	(1,800,000)
Notes Payable, Noncurrent		$ 7,580,000	$ 5,400,000	$ 1,800,000

Schedule of Fair Value of Notes

Schedule of Fair Value of Notes Payable (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Debt Disclosure [Abstract]
Balance as of December 31, 2021			$ 5,282
Addition of notes payable			5,000
Payment			(450)
Original issuance discount			250
Change in fair value of notes payable	$ 823		1,212
Balance as of September 30, 2022	$ 11,294		$ 11,294

Notes Payable (Details Narrativ

Notes Payable (Details Narrative) - USD ($)			3 Months Ended	9 Months Ended
	Feb. 21, 2022	Nov. 23, 2021	Sep. 30, 2022	Sep. 30, 2022	Dec. 31, 2021
Short-Term Debt [Line Items]
Note payable current			$ 831,000	$ 831,000	$ 696,000
Non-current note payable			3,499,000	3,499,000	5,282,000
Notes Payable, Fair Value Disclosure			11,294,000	11,294,000	5,282,000
Insurance Financing Note Payable [Member]
Short-Term Debt [Line Items]
Note payable current			831,000	831,000	$ 696,000
Total premiums, taxes and fees financed			915,000	$ 915,000
Annual interest rate				5.129%
Note Two [Member]
Short-Term Debt [Line Items]
Total Initial Fair Value At Issuance				$ 5,250,000
Two Notes [Member]
Short-Term Debt [Line Items]
Increase Decrease In Remeasurement Of Fair Value Recognized Expense			823,000	1,212,000
Deferral fees			220,000	247,000
Note payable current			7,795,000	7,795,000
Non-current note payable			3,499,000	3,499,000
Notes Payable, Fair Value Disclosure			11,294,000	11,294,000
Debt Instrument Increase Accrued Interest First Exercise [Member]
Short-Term Debt [Line Items]
Increase in unpaid interest	0.50%	0.50%
Debt Instrument Increase Accrued Interest Second Exercise [Member]
Short-Term Debt [Line Items]
Increase in unpaid interest	1%	1%
Debt Instrument Increase Accrued Interest Third Exercise [Member]
Short-Term Debt [Line Items]
Increase in unpaid interest	1.50%	1.50%
If prepayment occurs on or before three-month anniversary of the Issuance Date
Short-Term Debt [Line Items]
Percent of prepayment	105%	105%
If prepayment occurs after three-month anniversary of Issuance Date but on or before six-month anniversary of the Issuance Date
Short-Term Debt [Line Items]
Percent of prepayment	107.50%	107.50%
If prepayment occurs after six-month anniversary of Issuance Date
Short-Term Debt [Line Items]
Percent of prepayment	110%	110%
Streeterville Capital Llc [Member] | Note Purchase Agreement [Member]
Short-Term Debt [Line Items]
Aggregate loan amount granted	$ 5,250,000	$ 5,250,000
Original issue discount	$ 250,000	$ 250,000
Interest rate	6%	6%
Maturity date	Feb. 21, 2024	Nov. 23, 2023
Maximum monthly redemption amount	$ 450,000	$ 450,000	495,000
Debt Instrument, Periodic Payment, Principal			450,000	450,000
Prepayment premium (fee)			$ 45,000	$ 45,000

Warrants (Details Narrative)

Warrants (Details Narrative) - USD ($)	1 Months Ended			3 Months Ended	9 Months Ended
	Dec. 31, 2021	Aug. 31, 2021	Mar. 31, 2021	Sep. 30, 2022	Sep. 30, 2022	Sep. 30, 2021	Aug. 04, 2021
Subsidiary, Sale of Stock [Line Items]
Warrant to purchase number of common stock							2,473,778
Proceeds from issuance of common stock, net						$ 29,764,000
Exercise price of warrants							$ 5
Expected term				6 years	6 years	6 years
Expected volatility				99%
Risk-free interest-rate				3.45%
Dividend yield				0%	0%	0%
Prefunded Warrants [Member]
Subsidiary, Sale of Stock [Line Items]
Number of shares issuable per warrant	3,647,556
Warrant exercise price	$ 4,000
Securities Purchase Agreement [Member]
Subsidiary, Sale of Stock [Line Items]
Issuance of common stock		1,300,000	1,037,405
Combined purchase price for each common stock and accompanying warrant		$ 5.053
Combined purchase price for each pre-funded warrant and accompanying warrant		5.052
Difference between combined purchase price for each share of common stock and accompanying warrant to pre-funded warrant and accompanying warrant		$ 0.001
Gross proceeds from issuance of common stock		$ 25,000,000	$ 7,000,000
Proceeds from issuance of common stock, net		22,600,000	$ 6,400,000
Securities Purchase Agreement [Member] | Common Stock Shares and the Warrants Shares
Subsidiary, Sale of Stock [Line Items]
Proceeds from issuance of common stock, net		22,600,000
Relative fair value of the common stock shares		4,400,000
Relative fair value of the prefunded warrants		$ 12,200,000
Securities Purchase Agreement [Member] | Prefunded Warrants [Member]
Subsidiary, Sale of Stock [Line Items]
Warrant to purchase number of common stock		3,647,556
Combined purchase price for each pre-funded warrant and accompanying warrant		$ 5.052
Exercise price of warrants		$ 0.001
Percentage of ownership on issue of outstanding common stock for warrants		4.99%
Percentage on issue of outstanding common stock for warrants		0.0999
Securities Purchase Agreement [Member] | Warrant [Member]
Subsidiary, Sale of Stock [Line Items]
Warrant to purchase number of common stock		2,473,778
Number of shares issuable per warrant		1
Exercise price of warrants		$ 5
Expiration term of warrants		7 years
Percentage of ownership on issue of outstanding common stock for warrants		4.99%
Percentage on issue of outstanding common stock for warrants		0.0999
Expected term		7 years
Expected volatility		97%
Risk-free interest-rate		96%
Dividend yield		0%

Schedule of Common Stock Reserv

Schedule of Common Stock Reserved for Future Issuance (Details) shares in Thousands	Sep. 30, 2022 shares
Accumulated Other Comprehensive Income (Loss) [Line Items]
Total common stock for future issuance	6,418,754
Share-Based Payment Arrangement, Option [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Total common stock for future issuance	2,118,056
Future Options [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Total common stock for future issuance	765,502
Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Total common stock for future issuance	3,535,196

Common Stock (Details Narrative

Common Stock (Details Narrative) - USD ($)			1 Months Ended		3 Months Ended		9 Months Ended		12 Months Ended
	Jan. 19, 2022	Jul. 12, 2021	Aug. 31, 2021	Mar. 31, 2021	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Aug. 04, 2021
Subsidiary, Sale of Stock [Line Items]
Common stock, par value					$ 0.0001		$ 0.0001		$ 0.0001
Proceeds from issuance of common stock, net								$ 29,764,000
Dividend shares to its common stock stockholders			634,600	124,789			0
Research and development					$ 6,118,000	$ 19,842,000	$ 18,916,000	29,370,000
Warrant to purchase number of common stock										2,473,778
Issuance of common stock, pre-funded warrants and warrants in registered direct offerings, net of issuance costs						$ 23,294,000		$ 29,711,000
Stock Purchase Agreement [Member]
Subsidiary, Sale of Stock [Line Items]
Combined purchase price for each common stock and accompanying warrant			$ 5.053
Common Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Issuance of common stock pre-funded warrants and warrants in registered direct offering, net of issuance costs (in shares)						1,300,000		2,337,405
Dividend shares to its common stock stockholders						634,600		759,389
Fair value of dividend shares issued to common stockholders						$ 986,000		$ 3,100,000
Issuance of common stock, pre-funded warrants and warrants in registered direct offerings, net of issuance costs
Securities Purchase Agreement [Member]
Subsidiary, Sale of Stock [Line Items]
Issuance of common stock pre-funded warrants and warrants in registered direct offering, net of issuance costs (in shares)			1,300,000	1,037,405
Common stock, par value				$ 0.0001
Gross proceeds from issuance of common stock			$ 25,000,000	$ 7,000,000
Proceeds from issuance of common stock, net			$ 22,600,000	$ 6,400,000
Dividend shares to its common stock stockholders			634,600	124,789
Fair value of dividend shares issued to common stockholders			$ 3,100,000	$ 986,000
Combined purchase price for each common stock and accompanying warrant			$ 5.053
Combined purchase price for each pre-funded warrant and accompanying warrant			5.052
Difference between combined purchase price for each share of common stock and accompanying warrant to pre-funded warrant and accompanying warrant			$ 0.001
Securities Purchase Agreement [Member] | Prefunded Warrants [Member]
Subsidiary, Sale of Stock [Line Items]
Warrant to purchase number of common stock			3,647,556
Combined purchase price for each pre-funded warrant and accompanying warrant			$ 5.052
Securities Purchase Agreement [Member] | Warrant [Member]
Subsidiary, Sale of Stock [Line Items]
Warrant to purchase number of common stock			2,473,778
Securities Purchase Agreement [Member] | Investors [Member]
Subsidiary, Sale of Stock [Line Items]
Issuance of common stock pre-funded warrants and warrants in registered direct offering, net of issuance costs (in shares)			634,600	124,789
Medimmune Limited License Agreement [Member]
Subsidiary, Sale of Stock [Line Items]
Research and development									$ 6,500,000
Medimmune Limited License Agreement [Member] | Common Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Stock issued shares		884,956
Stock issued value		$ 6,500,000
At Rate Market Offering Agreement [Member]
Subsidiary, Sale of Stock [Line Items]
Common stock, par value	$ 0.0001
Issuance of common stock, pre-funded warrants and warrants in registered direct offerings, net of issuance costs	$ 25,000,000
Maximum commission	3%

Share-based Compensation, Stock

Share-based Compensation, Stock Options, Activity (Details) - $ / shares	3 Months Ended			9 Months Ended
	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2022	Sep. 30, 2021
Share-Based Payment Arrangement [Abstract]
Shares available for granted, begining	777,843	184,528	228,099	228,099
Number of Shares, beginning	2,105,715	1,949,030	1,905,459	1,905,459
Weighted-Average Exercise Price, beginning	$ 7.42	$ 8.24	$ 8.48	$ 8.48
Options granted	(35,000)	(258,934)	(85,635)
Number of Shares, Stock option granted	35,000	258,934	85,635	379,569	224,140
Weighted-Average Exercise Price, Options granted	$ 1.91	$ 1.06	$ 1.92
Options cancelled	22,659	102,249	42,064
Number of Shares, Options cancelled	(22,659)	(102,249)	(42,064)
Weighted-Average Exercise Price, Options cancelled	$ 5.61	$ 6.88	$ 5.80
Additional shares reserved		750,000
Shares available for granted, ending	765,502	777,843	184,528	765,502
Number of Shares, end of the period	2,118,056	2,105,715	1,949,030	2,118,056
Weighted-Average Exercise Price, ending	$ 7.35	$ 7.42	$ 8.24	$ 7.35

Schedule of Share-based Payment

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions (Details)	3 Months Ended	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2022	Sep. 30, 2021
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Expected term	6 years	6 years	6 years
Expected volatility	99%
Risk-free interest-rate	3.45%
Dividend yield	0%	0%	0%
Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Expected volatility		99%	99%
Risk-free interest-rate		1.72%	0.75%
Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Expected volatility		114%	100%
Risk-free interest-rate		3.45%	1.14%

Schedule of Employee Service Sh

Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total	$ 349	$ 580	$ 1,161	$ 1,700
Research and Development Expense [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total	159	170	385	502
General and Administrative Expense [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total	$ 190	$ 410	$ 776	$ 1,198

Stock-Based Compensation (Detai

Stock-Based Compensation (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended				9 Months Ended
	May 31, 2014	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Jun. 30, 2020
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares, stock option granted		35,000	258,934	85,635		379,569	224,140
Weighted-average grant date fair value		$ 1.53				$ 1	$ 5.04
Stock option exercised		0			0	0	0
Equity Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Vesting period	4 years
Expiration period	10 years
Share-Based Payment Arrangement, Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock option exercised							1,559
Intrinsic value of options							$ 5,000
Unrecognized stock-based compensation expenses related to stock options		$ 1,400,000				$ 1,400,000
Unrecognized stock-based compensation expenses expected to be recognized						2 years 8 months 1 day
Common Stock [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock option exercised							1,559
2014 Equity Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Reserved for issuance								2,183,692
2014 Equity Incentive Plan [Member] | Employees Directors and Consultants [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Reserved for issuance								750,000
2014 Equity Incentive Plan [Member] | Employees [Member] | Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Voting rights of all classes of stock	10%
2014 Equity Incentive Plan [Member] | Board of Directors [Member] | Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise price for incentive stock options to the percentage of fair market value	110%
2014 Equity Incentive Plan [Member] | Common Stock [Member] | Employees Directors and Consultants [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Reserved for issuance	233,722

Related Parties (Details Narrat

Related Parties (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended		9 Months Ended		12 Months Ended
	Jul. 31, 2019	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Related Party Transaction [Line Items]
Issuance of common stock, value			$ 23,294,000		$ 29,711,000
Deferred revenue		$ 20,386,000		$ 20,386,000		$ 20,838,000
Deferred revenue, noncurrent		737,000		737,000		913,000
Capitalized contract cost, current		1,986,000		1,986,000		1,967,000
Capitalized contract cost, noncurrent		78,000		78,000		96,000
Serum International BV [Member]
Related Party Transaction [Line Items]
Issuance of common stock, shares	801,820
Issuance of common stock, value	$ 10,000,000
Serum International BV [Member] | License [Member]
Related Party Transaction [Line Items]
Deferred revenue		18,900,000		18,900,000		18,700,000
Deferred revenue, noncurrent		737,000		737,000		854,000
Capitalized contract costs		2,100,000		2,100,000		2,100,000
Capitalized contract cost, current		2,000,000		2,000,000		2,000,000
Capitalized contract cost, noncurrent		78,000		78,000		90,000
Shenzen Hepalink Pharmaceutical Group Co Ltd [Member]
Related Party Transaction [Line Items]
Reduction to operating expenses on reimbursed to JV entity		$ 0	$ 14,000	0	$ 60,000
Shenzen Hepalink Pharmaceutical Group Co Ltd [Member] | Other Receivables [Member]
Related Party Transaction [Line Items]
Reduction to operating expenses on reimbursed to JV entity				$ 13,000		$ 28,000

Schedule of Operating Lease Ass

Schedule of Operating Lease Assets And Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Jan. 01, 2022	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
ROU assets, net	$ 1,532	$ 1,900
Current portion of lease liabilities (included in current liabilities)	526
Lease liabilities, less current portion	1,430
Operating Lease, Liability	$ 1,956	$ 2,300

Schedule of Future Minimum Rent

Schedule of Future Minimum Rental Payments for Operating Leases (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Jan. 01, 2022
Commitments and Contingencies Disclosure [Abstract]
Three months ending December 31, 2022	$ 153
Year ending December 31, 2023	628
Year ending December 31, 2024	646
Year ending December 31, 2025	666
Thereafter	57
Future minimum lease payments	2,150
Interest remaining	(194)
Total	$ 1,956	$ 2,300

Commitments and Contingencies_2

Commitments and Contingencies (Details Narrative)	1 Months Ended			9 Months Ended	12 Months Ended
	Feb. 28, 2021 USD ($)	Feb. 29, 2020 USD ($)	Dec. 31, 2016 USD ($) Item Installment	Sep. 30, 2022 USD ($)	Dec. 31, 2021 USD ($)	Jan. 01, 2022 USD ($)	Oct. 31, 2020 USD ($) ft²	Nov. 30, 2018 USD ($)
Loss Contingencies [Line Items]
Percentage of discount				6%
Percentage of discount						6%
Right-of-use assets, net				$ 1,532,000		$ 1,900,000
Operating lease				1,956,000		$ 2,300,000
Compensatory damages sought		$ 277,000
Original purchase price		$ 531,686.85
Liability recognized				0	0
Lease Agreement [Member]
Loss Contingencies [Line Items]
Area of building space | ft²							15,129
Leasehold improvements may be reimbursed							$ 378,000
Initial term							5 years
Renewal term							3 years
Amount of letter of credit as security deposit to the Landlord							$ 500,000
Arrangement Other than Collaborative [Member]
Loss Contingencies [Line Items]
Amount of award received for advance research on potential drugs			$ 2,900,000					$ 7,500,000
Excess amount recorded as liability				$ 0	$ 0
Number of multiplication on awarded amount payable prior to completion | Item			9
Period for payment of annual installments			90 days
Payments due on net sales up to net award received			15%
Payment due for revenue transaction			15%
Arrangement Other than Collaborative [Member] | Maximum [Member]
Loss Contingencies [Line Items]
Number of annual installments for repayment of award | Installment			5
Kermode Agreement
Loss Contingencies [Line Items]
Upfront payment received	$ 500,000
Kermode Agreement | Milestone One [Member]
Loss Contingencies [Line Items]
Milestone Payment Received	250,000
Kermode Agreement | Milestone Two [Member]
Loss Contingencies [Line Items]
Milestone Payment Received	$ 250,000

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($) $ / shares in Units, $ in Millions		1 Months Ended
	Aug. 04, 2021	Oct. 31, 2022
Subsequent Event [Line Items]
Warrants purchase	2,473,778
Warrant exercise price	$ 5
Reducing warrant exercise price	$ 2
Subsequent Event [Member] | Securities Purchase Agreement [Member]
Subsequent Event [Line Items]
Issuance of common stock pre-funded warrants and warrants in registered direct offering, net of issuance costs (in shares)		1,800,000
Warrants purchase		7,207,208
Offering price per share		$ 1.11
Warrant exercise price		$ 1.11
Proceeds from issuance of warrants		$ 8
Proceeds from issuance of warrants		$ 7.8
Subsequent Event [Member] | Securities Purchase Agreement [Member] | Warrant [Member]
Subsequent Event [Line Items]
Warrants purchase		5,407,208
Offering price per share		$ 1.109